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ABSTRACT 
 
6-Aryl-9-substituted benzylpurines as antimycobacterial agents have been previously 
studied in our group.1-5 The structural activity relationship (SAR) of antimycobacterial 
purines is generally well understood5 (Figure 1, compound 1). We have decided, after 
exploring the SAR of intact purines to investigate the activity of pyrimidine analogs of 6-
aryl-9-substituted benzylpurines antimycobacterial agents. Herein we discuss the 
synthesis of 6-aryl-4-substituted benzylpyrimidines (Figure 1, compound 2) and 
antimycobacterial activity of these compounds found to date.  
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Figure 1. Summary of SAR knowledge for 6-aryl-9-benzylpurines (1).5 Pyrimidine 
scaffold (2) studied herein. 
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ABBREVIATIONS 
 
AIDS Acquired immunodeficiency syndrome 
ATCC American type culture collection 
Bu Butyl 
DCM Dichloromethane 
DMF Dimethylformamide 
DNA Deoxyribonucleic acid 
DOTS Directly observed treatment and short-course 
HIV Human immunodeficiency virus 
HMBC Heteronuclear multiple bond correlation experiment 
HMQC Heteronuclear multiple-quantum coherance experiment 
HOMO Highest occupied molecular orbital 
IUPAC International union of pure and applied chemistry 
L Ligand 
LDA Lithium diisopropylamide 
LTBI Latent tuberculosis infection 
LUMO Lowest unoccupied molecular orbital 
MAPc Tidoglycan complex 
MDR Multi drug resistant tuberculosis 
Me Methyl 
MIC Minimum inhibitory concentration  
Mtb Mycobacterium tuberculosis 
NAD Nicotinamide adenine diinucleotide 
n.d. Not tested 
NEt3 Triethylamine 
NMR Nuclear magnetic resonance spectroscopy 
NOESY Nuclear overhauser effect spectroscopy 
Ph Phenyl 
R Hydrocarbon 
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RNA Ribonucleic acid  
r.t. Room temperature 
SAR Structure activity relationship 
SNAr Nucleophilic aromatic substitution  
TAACF Tuberculosis anticrobial acquisition and coordinating facility 
TB Tuberculosis 
TBAB Tetrabutylammonium bromide 
THF Tetrahydrofuran 
WHO World health organisation 
XDR Extensive drug resistant tuberculosis 
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1. INTRODUCTION 
 
6-Aryl-9-substituted benzylpurines as antimycobacterial agents have been previously 
studied in our group.1-5 The structural activity relationship (SAR) of antimycobacterial 
purines is generally well understood. We have decided, after exploring the SAR of intact 
purines to investigate the activity of pyrimidine analogs of 6-aryl-9-substituted 
benzylpurines as antimycobacterial agents. Herein we discuss the synthesis of 6-(2-
furanyl)pyrimidines carrying a benzyloxy or benzylamine group in the pyrimidine 4-
position as well as additional substituents in the 2 or 5-position, and antimycobacterial 
activity for these compounds, found to date. To understand the reason for designing new 
antimycobacterial agents, there is; a general introduction which explains the current 
situation of tuberculosis (TB) including, prevalence, current treatment and other topics 
which are important for drawing of a picture of a world, requiring new drug for the 
treatment of TB, as soon as possible. This is followed by a section looking at the past 
work performed on antimycobacterial purines, which are the molecules that 
antimycobacterial pyrimidines have been developed from. Then there is a section 
explaining the common chemistry used for the synthesis of antimycobacterial 
pyrimidines. The next part is an in-depth look at the synthesis performed within this 
thesis of antimycobacterial pyrimidines. Followed by, a discussion of the results of 
biological testing which have been received to date. The report is finished off with 
possible future research which has resulted form work performed herein, conclusion 
discussing what has been achieved herein, and finally the experimental section, appendix, 
and reference list. 
.  
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1.1 Tuberculosis – the disease and current treatments 
 
This section gives an overview of tuberculosis and the currently available treatments 
 
1.1.1 The disease 
 
Every second, one person is infected with the Tuberculosis (TB) bacilli.6 TB is the 
number two infectious cause of death today, only toped by Human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS).7 It is estimated that one third 
of the world’s population – 1.86 billion people are today infected with TB bacilli,6 with 
nearly 9 million new cases a year and close to 3 million deaths reported.8 Coupled with 
HIV, TB incidence is escalating more rapidly than it otherwise would. HIV destroys the 
immune system of people allowing latent infections of TB become active infections at a 
higher rate of occurrence, with an rising rate of infection activation of 5-15% for every 
year of HIV infection.9 TB is spread from actively infected individuals through the air 
along much the same means as the influenza, that is water droplets expelled during 
coughing, sneezing or talking and is primarily transmitted via the respiratory tract.10 If 
untreated, someone with an active TB infection can, on average, infect 10 to 15 people 
per year.11 It is believed that if it where not for HIV, tuberculosis would now be in a 
decline in nearly all countries around the world.12 
 
Africa and the former Soviet Union are the only places where TB occurrence is on the 
rise, at a reported rate of over 6 % between 1997 and 2000. This, however is enough to 
mean that the global incidence of TB is rising by 1% per year.13-16 HIV can be clearly 
seen as the underlying factor in this huge increase, combined with the breakdown of TB 
control programmes.12, 16 Of the 3 million deaths reported, the highest death rates and per 
capita where found in the African region where the high incidence of HIV and TB co-
infection can be partially blamed for the high death rates per percentage TB infection.8, 12 
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1.1.2 The micro-organism 
 
TB is caused by an infection of Mycobacterium tuberculosis (Mtb) which is an acid-fast 
bacilli bacterium from the genus Mycobacterium. Characteristic of this genus, Mtb has 
very slow colony growth rates and cell walls which are rich in lipid content, containing 
large amounts of C60-C90 fatty acids, and mycolic acids, that are covalently linked to 
arabinogalactan (Figure 2).17 The lipid rich cell wall forms a thick protective layer which 
is thought to be responsible for mycobacterium pathogenicity or virulence, drug 
resistance, resistance to common antibiotics and chemotherapeutic agents cell 
permeability, immunoreactivity, inhibition of antigen responsiveness, and disease 
persistence.10, 17 The high lipid content of the Mtb cell walls also result in a degree of 
hydrophobicity and resistance to acids, alkali, alcohols and many disinfectants.10 
 
 
Figure 2. The mycobacterium cell wall structure.17 
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1.1.3 Current drugs in use 
 
The currently recommended therapy for TB is a regimen of four drugs – isoniazid, 
rifampicin, pyrazinamide, and ethambutol (Figure 3). – Taken daily for two months, 
followed by isoniazid and rifampicin for a further 4 months.18-20 
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Figure 3. Chemical structure of the four first line drugs currently used for treatment M. 
tuberculosis infections, both latent and active infections. 
 
A long period of treatment is required to reduce the risk of TB bacilli surviving and 
developing drug resistance.19 If first line drugs fail due to drug resistance, second line 
drugs such as: cycloserine, ethionamide, levofloxacin, moxifloxacin, ciprofloxacin, p-
aminosalicylic acid, streptomycin and amikacin/kanamycin (Figure 4) are used.18,20 
Second line drugs are not favoured for treatment due to longer treatment times - of up to 
24 months,21 higher failure rates due to drug resistance, with a probability for resistance 
of approximately 10-3 (0.1 %) compared to first line drugs which have a probability of 
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resistance of 10-6 to 10-8,16 increased drug toxicity and increased chance of secondary 
infections.8 
O
O
O
O
OH
OH
HO
NH2
NH2
OH
OH
OH
H2N
O OH
H2N
OH
NH
O
H2N
O
N
S
H2N
N
O
N
N
F
O
HO
O
N N
NH
FHO
O O
N
O O
OHF
N
OH3CNH
HO
HO
O
NH2
O
O
O
O
HO
OH
OH
NHH2N
NH
HN NH2
NH
CHO
HO
OH
HO
OH
OH
N
CH3
Cycloserine Ethionamide p -Aminosalicyclic acid Levof loxacin
Moxif loxacinCiprof loxacin
Amikacin
Streptomycin  
Figure 4. Chemical structure of eight second line drugs currently used for treatment of 
M. tuberculosis infections, both latent and active infections. 
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1.1.4 Directly-observed treatment and short-course  
 
Directly-observed treatment and short course (DOTS) is the world health organisation 
(WHO) strategy for the stopping of the global tuberculosis epidemic which was first 
introduced in 1995, now better known as the broader public-health strategy. The DOTS 
treatment course includes diagnosis by sputum-smear microscopy, methods for 
supporting patients for 6-8 months of treatment, systems to insure uninterrupted drug 
supplies, and for recording and reporting. There is a great deal of evidence that, when all 
the recommended procedures are followed, as set out by DOTS, chemotherapy under 
DOTS can result in successful treatment of 90 % or more of TB cases and reduce the 
incidence of TB developing drug resistance. However in populations where resistance has 
already spread because of poor treatment in the past, the DOTS treatment course has 
much higher rates of treatment failure resulting in higher death rates.22 The DOTS 
treatment course is diagnosis by sputum-smear microscopy, which can provide less than 
50 % positive results in newly infected patients and it does not identify drug resistance.23 
Drug resistance is most commonly only identified after TB has not responded to the 
initial treatment, which can lead to further drug resistance.23 Currently methods for 
confirmation of drug resistance can only be performed by slow, laborious, costly 
laboratory methods.16 
 
1.1.5 Drug resistance 
 
In recent years Mtb has been found in an increasing number of cases to be multi drug 
resistant (MDR), and recently a small number of TB infections have been found that are 
extensively resistant (XDR). Where MDR is defined as resistance to at least the two most 
potent first line drugs, isoniazid and rifampicin, and XDR is defined as resistance to at 
least three of the available six second line drugs, as well as been resistant to the first line 
drugs isoniazid and rifampicin, (Figures 3 and 4).24 Improper treatment of MDR, such as 
using too few drugs, poor quality second line drugs, and failure to ensure the obedience 
to treatment, has lead to an ever escalating incidence of XDR.21 One estimate found that 
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4.3 %, or 425,000, of new and previously treated TB cases diagnosed worldwide in 2004 
were MDR, representing a 40 % increase since 2000.16, 25 An estimated 185,000 cases of 
MDR were from previously treated patients. 60 % of the total MDR can be accounted for 
by three countries – China, India, and the Russian federation – with incidence rates of up 
to 16 % MDR.25, 26 
 
1.1.6 The need for new drugs for treatment of Tuberculosis  
 
The reasons supporting development of new anti-tuberculosis drugs are in fact threefold; 
to shorten and simplify treatment of drug-susceptible TB infections, to create new drugs 
that Mtb has no resistance to (thereby increasing successful treatment rates of patients 
with MDR), and to provide more effective and efficient treatment of latent tuberculosis 
infection (LTBI).18, 27 The potential impact of the development of new drugs which result 
in shorter treatment times, from the now 6 months or more, to 2 months, has been 
estimated to give a potential reduction of 40% in incidence and mortality by 2030 for 
TB.28 One of the greatest achievements of development of shorter course TB drugs would 
be the increased patient obedience and less need for long term supervision, reducing the 
chances of drug resistance developing.27 
 
No new drugs have been brought in to use directly aimed for the treatment of TB in over 
30 years. There have been an ever increasing number of drug resistant cases of TB 
observed in recent years, due to the lack of new drugs.27 WHO readily admits that DOTS 
in certain parts of the world, such as Africa where the prevalence of MDR coupled with 
HIV infection, will not be successful in reducing the rates of TB infections and deaths 
without the introduction of new resources such as, new drugs, scientific research, and 
effective strategies identifying both TB and HIV co-infected patients.16 Treatment of 
MDR is, in addition, currently very expensive, at approximately 100 times more costly 
than treating non drug resistant TB, which puts further strain on already under funded 
health care systems of developing countries.16 
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1.2 ANTIMYCOBACTERIAL PURINE DEVELOPMENT 
 
This section provides an overview of past work performed within our research group, on 
antimycobacterial purines. 
 
In Figure 5 the standard International Union of Pure and Applied Chemistry (IUPAC) 
numbering system that is used for purines and pyrimidines within this thesis can be 
seen.29 
 
 
Figure 5. Purine and pyrimidine numbering system 
 
1.2.1 Methods for development of new drugs 
 
New drugs can be developed in several ways; an existing drug can be chemically adapted 
to improve its pharmacokinetic properties and to make it less susceptible to the known 
mechanisms of resistance, or new drugs can be developed from lead molecules.30 The 
purine and pyrimidine antimycobacterial compounds worked on within our group have 
been developed from the lead molecules, 9-benzyl-2-chloro-6-(thiophen-2-yl)-9H-purine, 
and 9-benzyl-2-chloro-6-(furan-2-yl)-9H-purine  (Figure 6).5 
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Figure 6. Lead molecules, 9-benzyl-2-chloro-6-(thiophen-2-yl)-9H-purine and 9-benzyl-
2-chloro-6-(furan-2-yl)-9H-purine.5 
 
1.2.2 Development of antimycobacterial purines 
 
The chemistry performed on purine analogs in previous work has developed from the 
lead molecules 9-benzyl-2-chloro-6-(thiophen-2-yl)-9H-purine and 9-benzyl-2-chloro-6-
(furan-2-yl)-9H-purine (Figure 6).1-5 Which showed antimycobacterial activity when 
tested in vitro against Mtb H37RV in 2000 by Bakkestuen, et al.1 Antimycobacterial 
purines were identified through screening, and their modes of antimycobacterial action 
are currently poorly understood.1-5 The development of purine analogs as 
antimycobacterial compounds has subsequently been preformed by trial and error to work 
out the structure activity relationship (SAR) of antimycobacterial purine compounds 
whilst improving antimycobacterial activity. From 2000 to 2001, a large number of 
analogues of 9-benzylpurines were synthesised.1 Several of these 9-benzylpurines where 
found to exhibit inhibitory activities against Mtb (Table 1). Of the compounds tested in 
vitro with Mtb H37RV (ATCC 27294), 2-Chloro-6-(2-furyl)purine (Figure 7) showed the 
best MIC value of 0.78 µg/mL. The first line drug rifampicin (Figure 3, page 12) had a 
minimum inhibitory concentration (MIC) value of 0.25 µg/mL in the same assay.2  
Through a stepwise development programme starting with analogues of 9-benzylpurines 
as lead compounds, a variety of compounds have been substituted in the 2- 6- and/or 8-
position as well as on the benzyl group. Antimycobacterial activity has been determined 
by in vitro screening of the substituents against Mtb H37RV and high antimycobacterial 
activity was found for some of the purines synthesised.   
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Table 1. 9-Benzylpurines that were found to exhibit inhibitory activities against Mtb. 
X Y MIC µg/mL 
H H 3.131 
Cl H 0.781 
H OMe 1.563 
Cl OMe 0.393  
 
 
 
Figure 7. 2-Chloro-6-(2-furyl)purine 
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1.2.3 Current structure activity relationship information for 
antimycobacterial purines 
 
In the course of the stepwise development programme - following the best lead - the 
compounds that showed the best MIC value have been further developed. The following 
structure activity relationship (SAR) of the antimycobacterial purines has been identified 
as critical for antimycobacterial activity of purines (Figure 8).  
 
 
Figure 8. Current structure activity relationship (SAR) knowledge for antimycobacterial 
purines, recognized requirements for active antimycobacterial compounds.1-5 
 
From a published SAR study it was found that among the 6-arylsubstiuents tested, 2-furyl 
in the 6-position gave the most active compounds and that the benzylic moiety should be 
unsubtituted in the ortho- and alpha-positions.3 Several substituents where tolerated in 
the meta- and para-positions, and a methoxy group in the para-position seemed to result 
in the most active compound. The para-methoxy substituent generally increased 
antimycobacterial activity in addition to decreasing toxicity towards mammalian cells. 
Purines carrying C-2 substituents with different electronic properties, (F, Cl, OMe, SMe, 
Me) exhibited good inhibitory effect against Mtb. This indicates that the electronic 
properties of the substituents have only mild effect on the antimycobacterial activity. 
However substituent size appears to be a good deal more important for biological 
activity; activity generally decreases as the size of the substituent in the purine 2-postion 
increases (Figure 8).31 The most active antimycobacterial purines found to date are shown 
in Figure 9. 
 19
  
 
 
 
 
X = Cl, MIC 0.39 µg/mL 
X = F, MIC 0.39 µg/mL 
X = CH3, MIC 0.20 µg/mL 
 
 
Figure 9. Most active antimycobacterial purine analogs synthesised and tested to date. 
MIC values where calculated through in vitro testing with Mtb H37RV (ATCC 27294).  
 
The best MIC value of 0.20 µg/mL, (Figure 9) can be compared to a first line drug, 
rifampicin which has a MIC value of 0.25 µg/mL when tested under the same conditions 
against  Mtb H37RV (ATCC 27294).2 
 
1.2.4 Mechanism of action of antimycobacterial purines  
 
Many of the drugs available today for the treatment of TB have been studied 
comprehensively and their mechanism of action are understood (Table 2). However, to 
recognize the mechanism of action takes intensive study, which is often not performed 
until the drug is on the market.8 
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Table 2. Mechanism of action of currently available drugs used for the treatment of TB.8 
Drug Mode of action 
First-line drugs  
Isoniazid Prevents mycolic acid biosynthesis in cell 
wall 
Rifampicin Binds bacterial RNA polymerase 
Pyrazineamide Effects on pH and possibly on NAD 
biosynthesis 
Ethambutol Disrupts arabinogalactan layer biosynthesis 
Aminoglycosides (Injectable). Disrupt protein synthesis 
Fluoroquinolones  Interfere with DNA gyrase/topoisomerase 
Second-line drugs  
Ethionamide Interferes mycolic acid biosynthesis 
Cycloserine Prevents D-serine insertion into 
peptidoglycan 
p-aminosalicyclic acid Folic acid biosynthesis antagonist 
Clofazimine Action not known 
Thiaacetazone Action not known 
 
 
Consequently the mechanism by which antimycobacterial purines exhibit their anti TB 
activity is unidentified. A lack of cross resistance with many of the commonly used TB 
drugs, indicates that antimycobacterial purines do not have the same mode of action as 
rifampicin, kanamycin, ciprofloxacin, isonazid, and ethambutol, Figures 3 and 4 (pages 
12 and 13).2 The purine, 2-methyl-6-furyl-9-(p-methoxybenzyl)purine has be shown in 
vitro to have very little activity against the Gram positive bacteria Lactobacillus casei, 
indicating a selective mode of action against mycobacterial targets.2 Results of in vivo 
testing have also indicated that 2-methyl-6-furyl-9-(p-methoxybenzyl)purine can attack 
Mtb within macrophages, a very important factor of a anti TB drug if it is going to be 
effective against latent TB infections.2 Macrophages are cells within the tissues that 
originate from white blood cells called monocytes. Monocytes and macrophages are 
phagocytes, acting in non-specific defence or innate immunity, as well as specific 
defence.32 TB is hidden from the bodies defensive system within macrophages, therefore 
a successful drug must attack TB within macrophages.32 
 
 
 21
1.3 PREVIOUS DEVELOPMENT OF ANTIMYCOBACTERIAL NON-
PURINE ANALOGS IN OUR GROUP  
 
To date the SAR of intact purine antimycobacterial agents is generally well understood, 
while on the other hand, compounds lacking a purine ring have not been tested in depth. 
Therefore the significance of the purine ring for the SAR of the antimycobacterial 
compounds is unknown. In the next development step, compounds containing a 
pyrimidine ring in place of the purine ring, whilst still containing the substituents 
identified as critical for anti TB activity in antimycobacterial purines were synthesised 
and tested in vitro for antimycobacterial activity.    
 
1.3.1 Pyrimidine target molecules 
 
Brændvang, et al. found that 2-Chloro-4-(2-furyl)pyrimidine was essentially inactive 
against Mtb.31 Brændvang, et al. what's more, found that, on antimycobacterial purines, 
the presence of the benzyl substituent is vital for antimycobacterial activity.31 Therefore, 
it was decided to create a series of pyrimidine analogs carrying, both the 2-furyl and the 
benzyl group. Formamidopyrimidines (which are pyrimidines with a formamide group in 
the 5-poisition) were readily available by ring opening of purines (Scheme 1). A series of 
previously synthesised antimycobacterial purines, which generally showed profound 
antimycobacterial activity, were therefore chosen as starting materials. One of this ring 
formamidopyrimidines, that is N-4-(furan-2-yl)-6-(4-methoxybenzylamino)-2-
nitropyrimidin-5-yl)formamide was found to be more active against Mtb than its parent 
purine compound at the same time as having lower toxicity to mammalian cells (Table 
3).31 
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Scheme 1. Ring opening of purines, to give formamidopyrimidines. 31 
 
Table 3. Formamidopyrimidines biological test results (Scheme 1).31 
R2 R5 X MIC M. 
tuberculosis 
H37Rv 
(μg/mL)b 
IC90 M. 
tuberculosis 
H37Rv 
(μg/mL) 
IC50 M. 
tuberculosis  
H37Rv 
(μg/mL) 
IC50 
VERO 
cells 
(μg/mL) 
NO2 NHCHO NH 0.78 T t >62.5 
F NHCHO NH n.d. <0.2 <0.2 t 
Cl NHCHO NH n.d. 0.197 <0.2 t 
CF3 NHCHO NH n.d. 0.577 0.256 t 
CH3 NHCHO NH n.d. 0.333 <0.2 t 
CH2CH3 NHCHO NH n.d. 0.529 0.258 t 
OCH3 NHCHO NH n.d. 1.537 0.529 n.d. 
N(CH3)2 NHCHO NH n.d. 25.952 10.551 n.d. 
Key: t = Currently under testing. 
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The goal of this project was to further improve SAR knowledge for antimycobacterial 
pyrimidines, while possibly further improving the antimycobacterial activity for this class 
of compounds. As can be seen in Table 3, the effect of substituents in the pyrimidine 2-
position is generally well understood. However the effect of different substituents in the 
pyrimidine 4- and 5-positions is not well understood. The aim of the project was to try to 
improve our knowledge of the effect substituents in the pyrimidine 4- and 5-positions 
have on the antimycobacterial activity of antimycobacterial pyrimidines (Figure 10).   
 
 
 
 
 
(R2): H, Cl 
(R5): H, NH2, NO2 
(X):  NH, NCH3, O 
Figure 10. Pyrimidine analogs which were synthesised and tested for antimycobacterial 
activity in vitro, by Tuberculosis Anticrobial Acquisition and Coordinating Facility 
(TAACF).  
 
1.3.2 Possible benefits of antimycobacterial pyrimidine over 
antimycobacterial purines 
 
A condition of TB drugs, is that they should be orally taken to ensure easy drug 
delivery.33 A good method to predict oral activity is the use of the Lipinski rule of five 
which states: for a compound to be an suitably orally active drug, the following 
subsequent criteria should be met; “five or fewer hydrogen-bond donors (OH and NH 
groups), ten or fewer hydrogen bond acceptors (notably N and O), a molecular weight 
under 500 gmol-1, and a calculated logP less than or equal to 5”.34 Compounds shown in 
Figure 10 have been calculated using ChemDraw® software package to have a slightly 
higher CLogP values than the purine analogs shown in Table 3 (page 23) ClogP is the 
predicted partition coefficient value. Since mycobacteriums are surrounded by a thick and 
waxy cell wall, antimycobacterial compounds must be reasonably lipophilic to penetrate 
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the cell wall. A ClogP within the range of 2-5 would be most suitable.4 A slight increase 
in CLogP could possibly lead to improved cell wall penetration and therefore improve the 
activity of the compounds, although this is only a speculation as the novel mechanism of 
antimycobacterial action for this class of compounds is unknown. On the basis of the 
Lipinski’s rule of five, including the calculations, the compounds shown in Figure 10 
were chosen as the target molecules for this master’s project. 
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1.4 CHEMISTRY 
 
This section discusses common chemistry involved in the synthesis of antimycobacterial 
pyrimidines. The Stille reaction was employed for the introduction of the furyl group 
(general structure See; Figure 10, page 24). The benzylamino or benzyloxy groups were 
introduced by nucleophilic aromatic substitution. An unexpected Diels-Alder reaction 
was discovered in the project (see, Chapter 2.2.4). 
 
1.4.1 Stille reaction  
 
Transition metal catalyzed reactions have had a major impact on organic chemistry. 
Notably, the Kumada-Corriu (magnesium-mediated), Negishi (zinc mediated), Suzuki-
Miyaura (boron mediated) and Stille (tin mediated) cross-coupling reactions have been 
widely used to obtain many targets in the field of new pharmaceutical products.35, 36 The 
Stille reaction, discovered in the late 1970’s by John K, is frequently used for the 
formation of C-C bonds,37 is generally highly selective and has a broad scope of use. It 
involves a reaction between an organotin compound and an alkylhalide in the presence of 
palladium and ligand, and results in the formation of a carbon-carbon bond between the 
alkyl groups in the two reagents (Scheme 2). The tolerance of the Stille reaction to many 
functional groups, such as carboxylic acid, ester, amide, nitro, ether, amine, hydroxyl 
ketone and aldehyde groups, makes it a tremendously useful synthetic tool.38, 39 The 
popularity of the Stille coupling reaction is also helped by trialkyl organotin species 
being readily available. These compounds are reasonably air and moisture stable, which 
can be explained by the covalent Sn-C bond, which is one of the most covalent bonds 
when compared to other cross coupling partners such as Li-C, Mg-C, Al-C, Zn-C, and B-
C bonds.35 The Stille reaction can in fact be performed in an open vessel, as long as the 
humidity is low enough as to not cause the hydrolysis of the acid chloride.33 
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Scheme 2. The Stille reaction. 
 
The mechanism of the Stille reaction is generally not well understood. Scheme 3 shows 
the generally accepted mechanism of the reaction, which can be broken up into three 
parts.  
 
 
Scheme 3. Generally accepted mechanism of the Stille reaction.38-41 
 
 
1. The oxidative addition of the organic halide to palladium0 resulting in 
organopalladiumII.  
 
2.  Transmetalation of the organopalladiumII compound with tetraorganotin compound to 
give a diorganopalladiumII compound and triorganotin halide. The tetraorganotin 
reagent transfers the first group rapidly to form trioganotin halide, while the second 
leaves about 100 times slower. Fortunately, different groups transfer selectively from 
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tin, sp3 groups such as simple alkyl groups (usually methyl or n-butyl) having the 
slowest transmetalation rates.42 Therefore, single acetylenic, vinyl, aryl, allyl, or 
benzyl groups transfer exclusively with the other three alkyl groups remaining 
attached to the tin.42 
 
3.  Reduction of palladiumII to palladium0 resulting in the formation of a new C-C bond 
and regeneration of the palladium catalyst.38-41, 43 
 
The active catalyst, palladium0 complex, which can either be generated from a suitable 
palladium0 precursor, such as Pd(PPh3)4 or the active palladium catalyst can be formed by 
reduction of a suitable palladiumII precursor such as (Ph3P)2PdCl2, where the organotin 
reagent acts as the reducing agent.39 Palladium0 complexes are nucleophilic and react 
readily with organic electrophiles in an oxidative addition reaction to produce palladiumII 
intermediate.39 The catalyst concentration, added triphenylphosphine, and oxygen affect 
the rate of reaction.  
 
One of the two major downfalls of the Stille reaction is the need to use toxic organotin 
reagents. Larger R groups can be attached to the tin to reduce the toxicity of the organotin 
reagent, but this still remains a problem. Table 4 shows the general trend of toxicity.  
 
 28
Table 4. Mammalian toxicity of organotin compounds.44 RnSnX4-na 
R n = 4 3 2 1 
Me 1.5 0.07 0.7 4 
Et 0.6 0.04 0.3 <0.008 
Bu >12 0.7 0.5 8 
Oct >7 >8 >10 9 
Ph  0.3   
aLD50 in mmol/kg for rats, by oral administration.  
X = other substituent, i.e. furan-2-yl, toxicity varies slightly with the changing of this 
substituent. 
 
The second major problem is that these organotin reagents are converted to tributyltin 
halides in the reaction, which are difficult to remove. Their non solubility in water 
excludes the possibility of removal by extraction. If the products of the reaction are 
soluble in polar solvents, the reaction mixture can be stirred with an alcoholic solution of 
KF, ensuing in the formation of trialkyl- and triaryltin fluorides, which have high melting 
points, are non-volatile, and are insoluble in both organic solvents and water.45 The 
insoluble organotin fluoride can then be removed by flash chromatography on silica gel 
from the reaction products. However if the reaction products contain a good leaving 
group this method can result in a nucleophilic substitution reaction and the introduction 
of an alkyloxy group.46 This can sometimes be overcome by removal of tributyltin 
chloride by extracting the reaction mixture in acetonitrile and then removing the 
tributyltin chloride with hexane.46 
 
Biological data for the purines previously synthesised by Braendvang et al. (Figure 8, 
page 19) showed that a 2-furyl group in the purine 6-position is required for 
antimycobacterial activity.46 The furan group was introduced using the Stille reaction, a 
palladium metal catalyzed reaction. Even though the Stille reaction requires the use of 
toxic tin reagents,47 it was chosen for the introduction of the furan group due to, 
commercial availability of the tributyl(furan-2-yl)stannane starting material,  background 
knowledge within our group on Stille C-C bond forming reactions, and the stability and 
tolerance of the Stille reaction to functional groups. Several compounds have been 
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synthesised in the pharmaceutical industry using the Stille reaction, including among 
others, cis-Cefprozil an orally active antibiotic from Bristol-Meyers Squibb, 2-aryl and 2-
heteroaryl penems from SmithKline Beecham.35 
 
1.4.2 Nucleophilic aromatic substitutions on pyrimidine 
 
Pyrimidines with halogen substituents in activated 2-, 4-, and 6-positions are the basis of 
diverse modifications of the pyrimidine ring. The positions α and γ to an imine nitrogen 
are activated for the initial addition of a nucleophile by two factors: (i) inductive and 
mesomeric withdrawal of electrons by the nitrogens and (ii) inductive withdrawal of 
electrons by the halogen.48 Polyhalogenated compounds undergo regioselective and 
stepwise substitution reactions with soft nucleophiles such as hydroxide ion, alkoxides, 
mercaptides, and amines.48 In this two-step mechanism, the rate determining step is that 
which disturbs the aromaticity of the heterocycle – the nucleophile attacking and the 
formation of the Meisenheimer complex intermediate (Scheme 4).49 The second step 
restores aromaticity and is therefore faster, and involves the elimination of a negatively 
charged leaving group, most often a halide anion.48 The identity of the leaving group can 
only affect the rate of the first step, as this is the rate determining step. How good a 
leaving group the halide is has no to little effect on the rate of the reaction. Therefore, 
even though the C-F bond is very strong it does not slow the reaction down, as the 
inductive effect of fluoride on the C makes the first step particularly rapid compared to 
other halides,50, 51 
 
 
Scheme 4. Mechanism of nucleophilic aromatic substitution on pyrimidine (not all 
resonance forms for the intermediate are shown).49 
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Pyrimidine is most reactive to nucleophilic aromatic substitution in the pyrimidine 4/6 
positions closely followed by the pyrimidine 2-position.52 
 
 
1.4.3 Substituent effect on nucleophilic aromatic substitutions on 
pyrimidine 
 
Substituents can have a great deal of effect on the ability of pyrimidines to be involved, 
or not involved in nucleophilic aromatic substitution reactions. The Hammett substituent 
constant (σ) is a numerical description of the electron-donating or electron-withdrawing 
properties of a substituent relative to a hydrogen atom on a model reaction, when the 
substituent is attached to a benzene ring (Table 5).53 Where positive σ equal electron 
withdrawing effect and negative σ equal electron donating effect. Heteroaromatic rings 
belong to the limited family of substituents of the ‘push-pull’ type i.e. they are either able 
to withdraw or release electrons depending on the reaction. The 2-furyl group has been 
found previously to have moderate electron withdrawing inductive effect and is able to 
either withdraw or to release electrons by resonance effect. Not only the electronegativity 
of the heteroatom, but the overall inductive effect of the ring, must also be taken into 
account. This is influenced by many factors, including the value of the direction of the 
dipole moment, the geometry of the ring, the preferred conformation, and the possible 
formation of hydrogen bonds with the solvent.54   
 
Table 5. Hammett substituent constants.53, 55 
Group  σmeta σpara 
H 0 0 
Me -0.06 -0.14 
Et -0.07 -0.15 
F 0.34 0.15 
Cl 0.37 0.24 
Br 0.37 0.26 
NH2 -0.09 -0.57 
NMe2 -0.10 -0.63 
NO2 0.71 0.81 
OMe 0.10 -0.28 
2-furyl 0.06 0.02 
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1.4.4 Diels-Alder reaction  
 
The Diels-Alder reaction was first reported in 1928 by Diels and Alder.56 The Diels-
Alder reaction is a concerted [4 + 2] cycloaddition reaction. The reaction occurs in single 
step simply by heating. The charge transfer to the antibonding Lowest Unoccupied 
Molecular Orbital (LUMO) from the bonding Highest Occupied Molecular Orbital 
(HOMO) will cause the weakening, and accordingly the stretching, of both bonds. An 
increase in bond length will cause a lowering of the LUMO level and an elevation of the 
HOMO energy. Such interactions maybe helped by vibrational motion.57 The frontier 
molecular orbital is a generally good method for the prediction of the likelihood of a 
cycloaddition reaction occurring, where the two frontal orbital’s have the smallest energy 
gap between them.58 Electron poor dienes are known to react with both electron poor and 
electron rich dienophiles.58 Steric effects of major influence on the reactivity of diene-
dienophile Diels-Alder reactions are generally not found.58 Cyclic dienes that are 
permanently in the s-cis conformation are exceptionally good at Diels-Alder reactions, as 
the two ends of the diene can come close enough to react with the dienophile. Furan is 
permanently in the s-cis conformation and therefore reacts readily in Diels-Alder 
reactions. The lower aromaticity of furans when compared to, thiophenes, and pyrroles 
results in a much greater tendency of furan to undergo cycloadditions, as a 4-π, diene 
component in the Diels-Alder reaction.59 The Diels-Alder reaction does not occur when 
exposed to light, in the photochemical cycloaddition where one component is 
electronically excited as a result of the promotion of one electron from the HOMO to the 
LUMO*. The HOMO*-LUMO* orbital’s of the component of the excited state interact 
with the HOMO-LUMO orbital’s of the other component in the ground state (Figure 
11).60 Photochemical conditions allow [2+2] cycloaddition reactions to occur, but do not 
allow for Diels-Alder [4+2] cycloaddition. 
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LUMO
HOMO*
=
=
LUMO*
HOMO
 
Figure 11. Photochemical cycloaddition, one component is electronically excited as a 
consequence of the promotion of one electron from the HOMO to the LUMO* which 
makes [4+2] Diels-Alder cycloaddition impossible.60 
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2. SYNTHESIS OF TARGET MOLECULES 
 
In this section, synthesis of the target molecules is discussed in depth the target molecules 
being;  
 
• 4-(Furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a) 
• 4-(Furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-amine (10a) 
• 4-(Furan-2-yl)-6-(methoxybenzyloxy)-5-nitropyrimidine (12a)  
• 6-(Furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a) 
• N5-Ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a) 
• N5-Allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
• 6-(Furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine 
(27a) 
• 2-Chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a) 
• 2-Chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (41a) 
• 2-Chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy) pyrimidine (42a) 
• 4,6-Dichloro-5-methylpyrimidine (48a) 
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2.1 4-Substituted 6-(furan-2-yl)-5-nitropyrimidines 
 
The purpose of syntheses of the compounds 9a, 10a, and 12a (Figure 12), was to identify 
the effect of a strongly electron withdrawing group in the pyrimidine 5-position on the 
antimycobacterial properties of pyrimidines. In addition, to help identify the effect of 
different substituents in the pyrimidine 4-position of antimycobacterial properties of 
pyrimidines with strongly electron withdrawing groups on the pyrimidine 5-position. 
N
N NH
O
NO2
O
N
N N
O
NO2
O
N
N O
O
O
NO2
9a 10a 12a  
Figure 12. Target molecules for this section 
 
2.1.1 Effect of C-5 NO2 group on reactivity of pyrimidine to 
nucleophilic substitution 
 
NO2 is an ortho/para directing, electron withdrawing, and activating substituent for SNAr 
type reactions. A nitro group in the pyrimidine 5-positions is very activating for 
nucleophilic substitution of halogens in the C-2, C-4, and C-6 positions. Activation 
occurs both through electron withdrawal through resonance (Scheme 5) and through 
resonance stabilisation of the Meiserheimer complex (Scheme 6).  
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Scheme 5. Resonance stabilisation of cationic charge on 4,6-dichloro-5-nitropyrimdine. 
 
N
N
Cl
N O
O
Cl
Nu
N
N
Cl
N O
O
Cl
Nu
N
N
Nu
N O
O
Cl
Cl+
 
Scheme 6. Mechanism of nucleophilic aromatic substitution (SNAr) on 4,6-dichloro-5-
nitropyrimidine. 
 
Christiaan et al. found that the rate of halogen displacement also depends on the degree 
of nucleophilicity of the nucleophiles involved. The reaction rates were also dependent on 
temperature, and they were only able to introduce a second amine through nucleophilic 
substitution if an electron withdrawing group was present in the pyrimidine 5-position, 
such as NO2.61,62 
 
2.1.2 Synthesis of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-
amine (5a), N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine 
(5b), and 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-
amine (6a)  
 
For the reaction between (4-methoxyphenyl)methanamine (2a) and 4,6-dichloro-5-
nitropyrimidine (1a), two products were formed, 6-chloro-N-(4-methoxybenzyl)-5-
nitropyrimidine-4-amine (5a) and N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-
diamine (5b) in a ratio of 9:1, at a reaction temperature of -78 °C for 4 hours. It was also 
experimentally shown that by increasing the reaction temperature the yield of compound 
5b versus 5a increased and the opposite for reduction in temperature (Scheme 7, Table 
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6). The solvent was changed from n-butanol to dichloromethane, because n-butanol 
becomes very viscous at lower temperatures and this may have interfered with the 
reaction. 
 
N
N
Cl
X
O
NO2
5a, X = NH, 80 %
6a, X = NCH3, 72 %
7a, X = O, 0 %
N
N
X
X
O
NO2O
5b, X = NH, 6 %
6b, X = NCH3, 0 %
7b, X = O, 0 %
O
XH
2a, X = NH
3a, X = NCH3
4a, X = O
N
N
Cl
NO2
Cl
+ +
a, b or c
1a
 
Scheme 7. Reagents and conditions: a - (X = NH2), NEt3, DCM, 4 hours at -78 ºC  b - (X 
= NHCH3), NEt3, DCM, 3 hours at 0 ºC c - (X= O), NaH, THF, 24 hours at r.t.  
 
Table 6. Nucleophilic aromatic substitution reactions on 4,6-dichloro-5-nitropyrimdine 
(1a) with (4-methoxyphenyl)methanamine (2a) in the presence of NEt3. 
Solvent Reaction 
temp. 
(ºC) 
Reaction 
time 
(hrs.) 
Ratio 1a:1b 
from crude 
NMR 
Isolated 
5a (%) 
Isolated  
5b (%) 
n-butanol 120 24 0:1 0 32 
n-butanol 50 2 2:3 13 27 
DCM 0 1 3:2 51 13 
DCM -78 1 13:7 56 n.d 
DCM -78 1 n.d 64 15 
DCM -78 4 9:1 80 6.5 
 
For the substitution reaction involving 1-(4-methoxypenyl)-N-methylmethanamine (3a) 
only the wanted substituted pyrimidine 6a was formed at a reaction temperature of 0 °C. 
No further attempts where made to improve yields from 72 %. All attempts to synthesis 
compound 7a failed, however DeCroix showed a successful nucleophilic introduction of 
–OEt to 4,6-dichloro-5-nitropyrimidine (1a) in 20 % yield in much the same reaction 
conditions as used (Scheme 7).63 The reason why this reaction did not work is not 
understood. 
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2.1.3 Synthesis of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-
nitropyrimidin-4-amine (9a) and 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-
methyl-5-nitropyrimidine-6-amine (10a)  
 
Stille coupling of the 4-substituted 6-chloro-5-nitropyrimidines 5a and 6a with (2-
furyl)SnBu3 (8a) gave the desired 6-(2-furyl)-pyrimidines 9a and 10a in moderate yields 
(Scheme 8). 
 
 
Scheme 8. Reagents and conditions: a - (Ph3P)2PdCl2, DMF, 16 hours at 90 ºC.  
 
2.1.4 Synthesis of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a) and 
4,5-di(furan-2-yl)-5-nitropyrimidine (11b)  
 
As can be seen in Scheme 9 the amine can donate an electron pair to pyrimidine ring, 
thereby increasing the electron density within the aromatic ring. This makes the 
pyrimidine less susceptible to further nucleophilic attack. The furan ring, on the other 
hand, weakly withdraws electrons (Section 1.4.3), and therefore has an activating effect 
on nucleophilic aromatic substitution reactions. 
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Scheme 9. Resonance structures for amine electron donation to the pyrimidine ring.  
 
Because it was not possible to introduce the (4-methoxyphenyl)methoxy  group on to the 
un-substituted 4,6-dichloro-5-nitropyrimdine (1a), 4-chloro-6-(furan-2-yl)-5-
nitropyrimidine (11a) was synthesised to see if it would react successfully with 
sodium(4-methoxyphenyl)methoxide (Scheme 10). 
N
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NO2 N
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Scheme 10. Reagents and conditions: a - (Ph3P)2PdCl2, THF, 16 hours at r.t. b - 
Methanol, 24 hours at r.t. 
 
Because the furan group was found to be less deactivating for nucleophilic attack by the 
palladium catalyst as amines to the pyrimidine ring, disubtitution was much more 
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prevalent in the Stille couplings. The ratio of mono-substituted compound (11a) versus 
di-substituted compound (11b) was improved by increasing the equivalents of pyrimidine 
1a to (2-furyl)SnBu3 (8a) and reducing the reaction temperature (Table 7). The solvent 
was changed from DMF to THF because lower temperatures were used which did not 
require a high boiling solvent like DMF. Use of THF also allowed for easy removal of 
the reaction solvent during workup. 
 
Table 7. Reaction conditions used for the synthesis of 4-chloro-6-(furan-2-yl)-5-
nitropyrimidine (11a) and 4,5-di(furan-2-yl)-5-nitropyrimidine (11b) 
Solvent Reaction 
 temp. 
(ºC) 
Reaction  
time 
(hours) 
Eq. (2-
furyl)SnBu3) 
(%) yield 11a (%) yield 11b
DMF 40 15 1.1 44 62 
THF r.t. 24 0.5 73 20 
THF r.t. 16 1 35 30 
THF r.t. 16 1 45 17 
 
 
During workup with sat. sol. KF/MeOH nucleophilic substitution readily occurred on 
compound 11a resulting in the introduction of a methoxy group, analogous to the 
introduction of methoxy groups by Langli on electron poor purine systems.46 Removal of 
the tributyltin chloride by dissolving the reaction mixture in acetonitrile and then 
removing the tributyltin chloride with hexane was attempted unsuccessfully due to the 
solubility of the product in hexane. Finally the tributyltin chloride was removed 
successfully by changing the workup conditions to sat. sol. KF/THF.46 Compound 6a was 
treated with methanol which resulted in very good yields of 11c (Scheme 10, Page 40). 
This reaction resulted in complete conversion of compound 11a to compound 11c, 
showing that Pd, Sn, and KF were not necessary as catalysts for this reaction. 
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2.1.5 Synthesis of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-
nitropyrimidin-4-amine (9a) and 4-(furan-2-yl)-6-(4-
methoxybenzyloxy)-5-nitropyrimidine (12a) 
 
4-Cloro-6-(furan-2-yl)-5-nitropyrimidine (11a) was treated with 4-methoxybenzylamine 
(2a) or 4-methoxybenzylalcohol  (4a) to give the corresponding 4-subsituted 6-(2-furyl)-
5-nitropyrimidines 9a and 12a. (Scheme 11) 
 
N
N Cl
NO2
O HX
O
N
N X
O
NO2
O
9a, X = NH, 87 %
12a, X = O, 91 %
+
a or b
2a, X = NH, or
4a, X = O
11a
 
Scheme 11. Reagents and conditions: a - NEt3, DCM, 1 hour at – 78 ºC b - NaH, THF, 
3.5 hours at r.t.  
 
An excess of the nucleophilic reagents were used, which gave good yields of both 
compound 9a and compound 12a. This reaction sequence, that is introduction of the 
furan-2-yl into the pyrimidine 6-position followed by nucleophilic aromatic substitution 
to introduce the amine group, improved the overall yield to 80 % overall yield for 
compound 9a compared with 72 % that was obtained by introducing the amino 
substituent before the furan-2-yl (Schemes 7, 8, 10, and 11) to 80 % overall yield. The 
reaction shown in Scheme 11 was not attempted with X = NCH3, as compound 10a was 
already synthesised in sufficient quantities for all required testing.  
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2.2 N5-substituted 6-(2-furyl)-N4-(4-methoxybenzyl)pyrimidine-
4,5-diamines  
 
The purpose of the syntheses of compounds 22a, 23a, and 27a (Figure 12), was to 
observe if the activity of antimycobacterial pyrimidines with an amine in the pyrimidine 
5-position can be increased by the introduction of alkyl groups, which would have an 
effect on the steric nature of the resulting compounds, versus a primary amine in the 
pyrimidine 5-position. The primary amine analog of compounds 22a, 23a, and 27a, 6-
(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine, was previously shown to 
exhibit 0 % inhibition at 6.25 μg/mL concentration.31 
 
 
Figure 13. Target molecules for this section. 
 
2.2.1 General information on chemistry involved 
 
Direct alkylation reaction of 4,6-dichloropyrimidin-5-amine (13a) with alkyl halides in 
the presence of sodium hydride has previously been used successfully to introduce 
primary alkyl and allylic groups, but not secondary alkyl groups, most likely due to steric 
reasons.64 4,6-Dichloropyrimidine can be di-substituted with amines under conditions 
which do not lead to the disubstitution of 4,6-dichloropyrimidin-5-amine (13a),65 a good 
example of the deactivating effect of a amine substituent in the pyrimidine 5-position to 
nucleophilic attack on the pyrimidine ring. 
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2.2.2 Synthesis of 6-chloro-N4-(4-methoxybenzyl)-N5-
methylpyrimidine-4,5-diamine (17a), 6-chloro-N5-ethyl-N4-(4-
methoxybenzyl)pyrimidine-4,5-dimine (18a), N5-allyl-6-chloro-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (19a). 
 
4,6-Dichloropyrimidin-5-amine (13a) was reacted with iodomethane, iodoethane, and 
allylic bromide to give compounds 14a, 15a, and 16a, respectively, in good yields. 
Compounds 14a, 15a, and 16a were then reacted with (4-methoxyphenyl)methanamine 
(2a) to give compounds 17a, 18a, and 19a, respectively, in good to moderate yields. 
Amination of 4,6-dichloropyrimidin-5-amine (13a) was done with a large excess of the 
nucleophilic amine in harsh conditions to give mono substitution with no disubstituted 
product (Scheme 12).66-68 
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N
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R
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N
H
N
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O
c
17a R = -CH3, 90 %
18a R = -CH2CH3, 91 %
19a R = -CH2CHCH2, 45 %
13a
 
Scheme 12. Reagents and conditions: a - NaH, TBAB, alkyl iodide or allylic bromide, 
THF, 2 hours at r.t. b - NEt3, n-BuOH, 19 – 40 hours at 100 ºC c - trifuran-2-ylphosphine, 
tris(diphenylmethyliacetone)dipalladium, (2-furyl)SnBu3, DMF, 16 hours at 60 – 90 ºC.  
 
Pyrimidines 17a – 19a did not react successfully with (2-furyl)SnBu3 (8a). Compounds 
17a and 18a did not react with (2-furyl)SnBu3 (8a) most likely due to the deactivating 
effect of two amine substituents on the pyrimidine ring (Section 4.3). Starting material 
was recovered in both reactions. Compound 19a, when reacted with (2-furyl)SnBu3 (8a), 
lost its allylic side chain to give 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(33a) in 10 % yield. The mechanism by which the allylic side chain was removed is not 
known. Three possible alternatives have been found after a great deal of literature 
searches. The allylic side chain can be seen as a protecting group for the amine, which 
has been shown to be removed by catalytic transfer hydrogenation for the removal of 
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amine protecting groups requiring a hydrogen donor and Pd as a catalyst.69 The hydrogen 
donor can be the solvent, possibly meaning that this reaction occurred during the workup 
of the reaction. Alternatively the palladium may have catalysed the reactions shown in 
Scheme 13 and 14 resulting in the formation of 2-allyfuran which would have been lost 
during workup due to its volatility.70 
 
 
Scheme 13. Possible mechanism 1 for loss of allylic side chain as discussed by Trost et 
al.70 
 
 
Scheme 14. Possible mechanism 2 for loss of allylic side chain as discussed by Trost e
2.2.3 Synthesis of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-
ecause the synthetic route attempted in Scheme 12 was not successful, an alterative 
t 
al.70 
 
methylpyrimidine-4,5-diamine (22a), N5-ethyl-6-(furan-2-yl)-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (23a) 
 
B
route was attempted, where the furan-2-yl group was introduced first followed by 
amination to give compounds 22a and 23a (Scheme 15). 
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Scheme 15. Reagents and conditions: a - Tri(2-furyl)phospine, trifuran-2-ylphosphine, 
tris(diphenylmethyliacetone)dipalladium, (2-furyl)SnBu3 (8a), DMF, 16 hours at 70 – 80 
ºC b - NEt3, (4-methoxyphenyl)methanamine (2a), n-BuOH, 24 hours at 100 ºC 
 
This synthetic route was not attempted for the preparation allyl-6-(furan-2-yl)-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (32a) as it was expected to have resulted in the 
loss of the allylic side chain again. Stille coupling with furan-2-ylSn(Bu)3 (8a) on the 
pyrimidines 14a and 15a (Scheme 15) gave low yields, due to the non-reactive nature of 
pyrimidines with an electron donating group in the C-5 position to nucleophilic attack in 
4- and 6-positions. The Stille reaction appears to have greater difficulty overcoming 
deactivating groups on the pyrimidine ring than nucleophilic amines. The oxidative 
addition of the organic halide to palladium0, can be seen as a nucleophilic substitution 
where the palladium0 is the nucleophilic species.39 Palladium0 is possibly not as 
nucleophilic as primary and secondary amines in the presence of triethylamine (Section 
1.4.1). The nucleophilic substitutions on the halides of compounds 20a and 21a gave 
good yields, possibly because the furyl group is weakly electron withdrawing and 
therefore activating for SNAr reactions compared with an amine group which is strongly 
electron donating and deactivating for SNAr reactions (Section 1.4.3).  
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2.2.4 Synthesis of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-
dimethylpyrimidine-4,5-diamine (27a) and 4-chloro-8,10a-epoxy-
5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline (28a) 
 
An alternative synthetic route was used for the preparation of compound 27a, to that used 
for compounds 22a and 23a, due to the availability of compound 24a as a starting 
material for the synthesis of compound 19a (Scheme 16). 
N
N
O
NH2
Cl
N
N
Cl
NH2
Cl
N
N
O
N
Cl
N
N
O
N
NH
O
a b c
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Scheme 16. Reagents and conditions: a - trifuran-2-ylphosphine, 
tris(dibenzylideacetone)dipalladium chloroform complex, (2-furyl)SnBu3, DMF, 16 
hours at 70 ºC b - NaH, TBAB, alkyl iodide THF, 2 hours at r.t. c - NEt3, (4-
methoxyphenyl)methanamine (2a), n-BuOH, 24 hours at 100 ºC  
 
Compound 25a was synthesised using an excess of iodomethane and NaH, no 
monosubstituted product was formed. A low yield of only 21 % was found for the 
synthesis of compound 27a possibly due to steric hindrance from two methyl groups on 
N-5. 
 
Compound 24a was also reacted with allylbromide and NaH to give 26a in good yields. 
On attempt to react allyamine 26a with (4-methoxyphenyl)methanamine (2a) (Scheme 
17), a Diels-Alders reaction took place (Section 1.4.4), where the allylic group acted as 
the dienophile and the furan as the diene, resulting is the formation of compound 28a. 
The structure of compound 28a was determined by 1H, 13C, HMQC and HMBC NMR 
(Spectra 49, 50, 140, and 141).  
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Scheme 17. a - NaH, TBAB, allylic bromide, THF, 2 hours at r.t. b - NEt3, (4-
methoxyphenyl)methanamine (2a), n-BuOH, 24 hours at 100 ºC  
 
 
The Diels-Alder reaction which produced an interesting molecule, namely, 4-chloro-
8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline (28a). This could 
possibly be an easy three step reaction which could lead to several different complex 
multicyclic structures. This molecule could be of biological interest and has been sent for 
biological testing.  
 
It may be possible to overcome the problem of the Diels-Alder reaction, by replacing the 
chlorines with fluoride (Scheme 18), which is a better leaving group for SNAr type 
reactions. Reduction of the reaction temperature should be possible and therefore 
reducing the likelihood of the Diels-alder cycloaddition reaction which generally requires 
heating, from occurring when compound 31a is reacted with (4-
methoxyphenyl)methanamine (2a). Scheme 18 shows a possible method of introducing 
fluorine onto the pyrimidine ring in place of chlorine, this was however not attempted in 
this thesis due to time constraints. 
 
 47
NN
NO2
Cl
N
N
NO2
F
N
N
NH2
F
a b
O O O
N
N
H
N
F
O
c
N
N
H
N
N
H
O
O
d
11a 29a 30a 31a
32a  
Scheme 18. Fluorination of 4-chloro-6-(furan2-yl)-5-nitropyrimidine as explained by 
Beaman and Brown (Scheme 16).71, 72Reagents and conditions: a - silver fluoride, 
nitrobenzene, 170 -180 ºC 45 min. b - nitrobenzene, tetralin, aqueous ferrous 
hydroxide.71, 72 c - NaH, TBAB, alkyl iodide or allylic bromide, THF, 2 hours at r.t. d - 
NEt3, (4-methoxyphenyl)methanamine, n-BuOH, 24 hours at unknown temperature. 
 
2.2.5 Synthesis of N4-allyl-6-(furan-2-yl)-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (34a) and N4,N5-diallyl-6-
(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34b) 
 
A final attempt was made to prepare N5-allyl-N4-(4-ethylbenzyl)-6-(furan-2-
yl)pyrimidine-4,5-diamine without the loss of the allylic side chain or a Diels-Alder type 
reaction occurring.  
 
 
Scheme 19. Reagents and conditions: a - NEt3, (4-methoxyphenyl)methanamine, n-
BuOH, 24 hours at 100 ºC b - NaH, TBAB, allylic bromide, THF, 2 hours at r.t.  
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 Pyrimidine 33a was prepared in moderate yields by reacting compound 24a with (4-
methoxyphenyl)methanamine (2a) (Scheme 19). Compound 33a was then reacted with 
allylic bromide in the presence of NaH and TBAB which unfortunately resulted in the 
formation of compounds 34a and 34b, N5-allyl-N4-(4-ethylbenzyl)-6-(furan-2-
yl)pyrimidine-4,5-diamine (32a) was not observed (Scheme 19). 40 % of starting 
material, 4-chloro-6-(furan-2-yl)pyrimidine-5-amine (24a) was left after 24 horrs at 100 
ºC with a moderate yield of compound 33a. The reason for this is unclear, the primary 
amino group in the C-5 position is very slightly less electron donating than secondary and 
tertiary amines, in the C-5 pyrimidine position (Section 1.4.4). So the opposite result 
would be expected using σ values (Scheme 19). The amine on the pyrimidine 4-position 
seems to be deprotonated first followed by the deprotonation of the amine on the 
pyrimidine 5-position. This is because the C-4 amine is on an electron poor carbon of the 
pyrimidine ring and this helps to stabilize the deprotonated amine. Whereas the amine on 
the C-5 position can be stabilized, but only if the aromaticity of the pyrimidine is broken. 
It is also on the most electron rich position of the pyrimidine ring which would help to 
destabilize the deprotonated amine. 
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2.3 4-Substituted 2-chloro-6-furan-2-ylpyrimidines  
 
Pyrimidines with hydrogen in the 2-position have been tested and show to have low 
antimycobacterial activity.73 However Brænvang et al. has shown that by substituting the 
hydrogen in the purine 2-position with chlorine the antimycobacterial activity can be 
greatly increased.5 The increase in antimycobacterial activity by introduction of chlorine 
into the 2-position, may have the same positive effect on antimycobacterial pyrimidines, 
this section tested that theory. The purpose of the synthesis of compounds 39a, 41a, and 
42a (Figure 14), was to test if exchanging chlorine for hydrogen in the pyrimidine 2-
poisiton has a positive effect on antimycobacterial activity.  
 
 
Figure 14. Target molecules for this section. 
 
2.3.1 Effect of three chlorine groups on pyrimidine 
 
The reactivity of 2,4,6-trichloropyrimidines to nucleophilic substitution of halides is C-
4/C-6 > C-2.52 Selectivity in the case of polyhalogenated pyrimidines is not always easy 
to achieve.13 Solvent effects can be used to increase the ratio of C-4/C-6 to C-2 
substitution, where polar solvents tend to increase the ratio of C-4/C-6 to C-2 
substitution.74 Mixtures of 4- and 2-substituted products have been obtained in previous 
studies involving neutral nitrogen nucleophiles in which the ratio of the two isomers was 
very just about statistical, namely 2:1 – 3:1, in optimised reaction conditions for 
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substitution in the C-4/C-6 positions.74 A dependence of the isomer ratio on the solvent 
identity has been clearly indicated in one previous study by Schomaker, and appears to 
roughly correspond to the polarity of the solvent.74 The more polar the solvent the greater 
the substitution in the C-4/C-6 positions versus the C-2 pyrimidine position. Separation 
of C-4 and C-2 substituted regioisomers can often be achieved by flash chromatography 
on silica gel.75 Substituents on the pyrimidine can have an effect on the selectivity of the 
other positions.76 When di-substitution occurs it generally occurs at the 2,6-positions but 
not the 4,6-positions.77 
 
2.3.2 Synthesis of 2,6-chloro-N-(4-methoxybenzyl)pyrimidine-4-amine 
(36a), 4,6-dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-2-amine 
(37a), and 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a) 
 
2,4,6-Trichloropyrimidine (35a) was reacted with (4-methoxyphenyl)methanamine (2a) 
to give compounds 36a and 36b in a ratio of 3:2. 2,4,6-Trichloropyrimidine (35a) was 
reacted with 1-(methoxyphenyl)-N-methylmethanamine (3a) to give compounds 37a and 
37b in a ratio of 7:3. (4-methoxyphenyl)methanolate was reacted with 2,4,6-
Trichloropyrimidine (35a) to give compounds 38a, 38b, and 38c in a ratio of 21:7:1 
(Scheme 20). 
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Scheme 20. Reagents and conditions: a - Sodium carbonate, (4-
methoxyphenyl)methanamine (2a) or 1-(4-methoxyphenyl)-N-methylmethanamine (3a), 
absolute ethanol, 3 to 24 hours at r.t. b - NaH, (4-methoxyphenyl)methanol (4a), THF, 16 
hours at 0 ºC to r.t. c and d - tris(diphenylmethyllideacetone)dipalladium, tri(2-
furyl)phosphine, (2-furyl)SnBu3 (8a), DMF, 16 hours at 60 to 90 ºC.  
 
A double SNAr reaction on 2,4,6-trichloropyrimidine (35a) when reacted with (4-
methoxyphenyl)methanolate (4a) was possible because the methoxygroup is a weakly 
electron withdrawing and therefore activating for SNAr type reactions (Section 1.4.3). 
Introduction of the furan-2-yl group using the Stille reaction was not successful for 
compounds 36a, 37a, and 38a most likely due to the deactivating effect of electron 
donating groups (Section 1.4.3). Compounds 36a and 37a showed extreme peak 
broadening in both 1H and 13C NMR requiring temperatures of 70 ºC for single peaks  to 
be seen in 1H NMR. The line broadening is most likely due to restricted rotation around 
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the nitrogen bond, which can be explained by the resonance forms shown in Scheme 21. 
It is interesting to note this effect was only seen in compounds with chlorine in the 
pyrimidine 2-position. 
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NCl
O
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Scheme 21. Resonance forms of compounds 36a and 37a, (not all resonance forms 
included). 
 
As can be seen in Table 8, the temperature and solvent had a great deal to play in the 
regio-selectivity of the nucleophilic substitution. For both the synthesis of compounds 
36a and 37a 0 ºC in ethanol was found to give the best results among the conditions tried. 
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Table 8. Optimization of the reaction condition for the synthesis of compounds 36a and 37b (Scheme 20). 
 
Moles 
(A) 
Eq.(B) R Solvent [A]/M Base Eq.(base) Temp. [ºC] Time 
[hours] 
% yield 
36b or 37b 
% yield 36a 
or 37a 
% Overall 
yield 
1 1 H CH2Cl2 0.1 NEt3 1.05 0 then 
r.t. 
4 then 
13 
31 43 74 
1 1 CH3 CH2Cl2 0.1 NEt3 1.05 0 then 
r.t. 
4 then 
13 
20 46 66 
1.5 0.67 CH3 CH2Cl2 0.15 NEt3 1.05 -78 then 
r.t. 
1 then 
36 
19 50 69 
2 2 H Ethanol 0.20 Na2CO3 
 
1.5 r.t. then 
rfx. 
12 then 
2 
15 35 50 
2 1 H Ethanol 0.20 Na2CO3 0.5 r.t. 5 28 44 72 
2 1 CH3 Ethanol 0.20 Na2CO3 0.5 r.t. 2 21 52 73 
4 1 H Ethanol 0.08 Na2CO3 1.5 0 3 25 46 71 
4 1 CH3 Ethanol 0.08 Na2CO3 1.5 0 3 25 60.5 85.5 
Key: A = 2,4,6-trichloropyrimidine (35a), B = (4-methoxyphenyl)methanamine (2a)
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2.3.3 Synthesis of  2,4-dichloro-6-(furan-2-yl)pyrimidine (40a), 2-
chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a), 2-
chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a), 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a) 
 
Because it was not possible to introduce the furyl group by Stille coupling in the 
synthesis of compounds 36a, 37a, and 38a, (Scheme 20) due to the deactivating effect of 
electron donating groups in the pyrimidine 4-position, the strategy was changed. 2,4,6-
Trichloropyrimidine (35a) was coupled with furan-2-yl using the Stille reaction first to 
give compounds 40a and 40b (Scheme 22). 
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O
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O
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N
N OCl
O
40c
d
35a
 
Scheme 22. Reagents and conditions: a - Tris(diphenylmethyllideacetone)dipalladium, 
tri(2-furyl)phosphine, (2-furyl)SnBu3 (8a), THF, 16 hours 30 ºC b = sodium carbonate, 
(4-methoxyphenyl)methanamine (2a) or 1-(4-methoxyphenyl)-N-methylamine (3a), 
absolute ethanol, 3 to 24 hours at r.t.  c - NaH, (4-methoxyphenyl)methanol (4a), THF, 
16 hours 0 ºC to r.t. d - Methanol, 24 hours at 50 ºC. 
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It was not possible to separate compound 40b from compound 40a through flash 
chromatography. Therefore, the yield of both isomers was therefore determined through 
1H NMR (Spectrum 77) of both isomers together, which showed a ratio of 10:1 40a:40b. 
Compound 40c was only produced when the reaction mixture was worked up with sat. 
aq. KF in MeOH, and the percentage yield was based purely on the time the reaction 
mixture was stirred with  aq. KF in MeOH. It was later found that compound 40a could 
not be reacted directly with methanol without presence of other reagents to give 
compound 40c, unlike compound 11a which could be reacted with methanol to give 
compound 11c (Section 2.1.4). This shows that compound 40a does not undergo SNAr 
type reaction as readily as the electron poor compound 11a. Attempts to separate the 
tributyltin chloride from the reaction mixture by dissolving the reaction mixture in 
acetonitrile and then removing the tributyltin chloride with hexane were unsuccessfully 
due to the solubility of the product in hexane.46 Finally the tributyltin chloride was 
removed successfully by changing the workup conditions from sat. aq. KF in MeOH to 
sat. sol. KF in THF. Compound 40a was then reacted with three different nucleophilic 
reagents to give compounds 39a, 39b, 41a, 42a, and 42b. Sodium carbonate was 
employed in step (b) (Schemes 20 and 22) to neutralize the liberated hydrogen chloride8. 
Amination of 2,4,6-trihalopyrimidines results in a mixture of positional isomers at C-2 
and C-4, respectively. 
 
To further prove the regiochemistry of compounds 39a, 41a, and 42a NOESY NMR was 
required. 
 
For compound 39a, (Spectra 162) no through space coupling could be seen between CH2 
and H-5 pyrimidine proton in the NOESY spectrum. 
 
For compound 41a, (Spectra 173) through space coupling could be seen between H-5 and 
-NCH3 in the NOESY spectrum. 
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For compound 42a, (Spectra 176) through space coupling could be seen between H-5 and 
CH2 in the NOESY spectrum. 
 
Compound 39a showed no through space coupling between CH2 and H-5, this does not 
mean that this is the incorrect regioisomer as restricted rotation around N-4 may have 
affect the shape of compound 39a. Compounds 41a and 42a both showed through space 
coupling between H-5 on the pyrimidine and benzyl side chain, further proving that they 
are the correct regioisomers. 
 
As can be seen in Table 9, the presence of a furyl group in the pyrimidine 6-position 
increases the nucleophilic aromatic substitution that occurs in the pyrimidine 4-position 
versus the pyrimidine 2-position, when compared to 2,4,6-trichloropyrimidine (35a), 
considerably. Substituents have been previously shown by Yukawa to effect 
regioselectivity,76 however the reason for the change in selectivity or in this case the 
increase of selectivity for the pyrimidine 4-position has not previously been studied and 
is not well understood. The attacking nucleophile also has an effect on the 
regioselectivity of substitution reactions on 2,4,6-trichloropyrimidine (35a) as has been 
previously shown by Zanda.78 Secondary amines give a higher ratio of 4/6-position 
substitution versus 2-position substitution when compared to primary amines and 
alkoxides (Table 9). The reason for this has not been studied in depth previously and 
therefore the reason for the change in regioselectivity is unknown. 
 
Table 9. Effect of substituent on selectivity of nucleophilic aromatic substitution reaction 
(refer to Schemes 20 and 22 for further details on reaction conditions) 
Starting material Compound  Ratio  
   
2,4,6-trichloropyrimidine 36a:36b  3:2 
2,4,6-trichloropyrimidine 37a:37b  7:3 
2,4,6-trichloropyrimidine 38a:38b  3:2 
 Average ratio a:b isomers ≈ 17:11 
   
2,4-dichloro-6-(furan-2-yl)pyrimidine 39a:39b  4:1 
2,4-dichloro-6-(furan-2-yl)pyrimidine 41a:41b  1:0 
2,4-dichloro-6-(furan-2-yl)pyrimidine 42a:42b  4:1 
 Average ratio a:b isomers ≈ 17:2 
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2.4 C-5 alkyl substituted 4,6-dichloropyrimidines 
 
The purpose of introduction of an alkyl substituent in the pyrimidine 5-position of 4,6-
dichloropyrimidine (43a) is to allow the easy synthesis of many new antimycobacterial 
pyrimidines with different substituents in the pyrimidine 5-position, namely phenyl, 
allylic and methyl group. Thereby further improving our SAR knowledge of 
antimycobacterial pyrimidines. This section describes the synthesis of 5-
methylpyrimidine (48a) (Figure 15) which most probably could be used for the synthesis 
of new potential antimycobacterial pyrimidines, see Scheme 27, page 68. 
 
        
N
N
Cl
Me
Cl
48a  
Figure 15. Target molecule for this section 
 
2.4.1 Direct metalation of the pyrimidine 5-position 
 
Direct metalation of 4,6-dichloropyrimidine (43a) in the C-5 position, followed by 
quenching with benzyl aldehyde was attempted several times following the method 
explained by Radinov et al.79, 80 Benzyl aldehyde was used as the electrophile in this case 
to follow the exact procedure as done by Radinov et al. However there was no success in 
this reaction (Table 10 and Scheme 23). In the literature yields of 60 to 84 % were 
reported.79, 80 
 
N
N
Cl
Cl
N
N
Cl
Cl
OH
a
43a 44a  
Scheme 23. Reagents and conditions: a – LDA or tert-BuLi, benzylaldehyde, THF, 3 hrs. 
to 4 hours at -78 to -15 ºC 
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 Table 10. Reaction conditions attempted for reaction shown in Scheme 23 
Reaction 
number 
Formation of 
LDA 
Metalation of 
pyrimidine 
Quenching with 
PhCHO 
Product
44a 
  Temp 
°C 
Time 
hours 
Temp 
°C 
Time 
hours 
Temp 
°C 
Time 
hours 
 
1 -78  1  -78  1 -78  1 none 
2 -78  1  -78  1 -78  16 none 
3 -15  1 -78  1 -78  1 none 
4 -15  1 -78  0 -78 then 
-15 °C  
1 then 2 none 
5 tert-
BuLi  
- -78  1 -78 then 
-15  
 
1 then 2 none 
 
2.4.2 Metal halide exchange in pyrimidine 5-position 
 
Because all attempts to directly metalate 4,6-dichloropyrimidine (43a) failed, metal 
halide exchange was attempted as an alternative approach to the introduction of new 
functional groups in the pyrimidine 5-position. This required the introduction of a 
halogen into the pyrimidine 5-position, followed by treatment with a strong base and 
quenching of the reaction with the wanted electrophile. Reaction of 4,6-
dichloropyrimidine  (43a) with Br2 in the presence of acetic acid did not result in the 
formation of 5-bromo-4,6-dichloropyrimidine (45a) (Scheme 24). Direct bromination of 
4,6-dichloropyrimidine was done using the condition shown in Scheme 24 to check to see 
if electron donating groups were necessary for bromination of pyrimidine. 
 
N
N
Cl
Cl
N
N
Cl
Cl
Bra
43a 45a  
Scheme 24. Reagents and condition: a - AcOH, Br2, 24 hours at 90 ºC 
 
 59
The presence of two ring electron withdrawing nitrogens reduces the reactivity of 
pyrimidine to electrophilic attack considerable when compared to benzene.81 
Electrophilic reactions can only take place at C-5 or the ring nitrogen atoms. Because 
pyrimidine is a π-deficient heterocycle electrophilic attack can only be achieved under 
normal conditions if at least one electron-donating group is present. If one or more 
electroning donating group is present halogentation, nitration, diazo coupling, 
sulfonation, formylation, and related reactions are all possible at the 5-position.82 
Therefore bromination was attempted again on 4,6-dihydroxypyrimidine (46a) (Scheme 
25) 
 
 
Scheme 25. Reagents and conditions: a - Br2, AcOH, 24 hours at 70 ºC.83 
 
This time the introduction of the bromine into the pyrimidine 5-position was successful 
due to the activating effect of the two electron donating oxygen molecules ortho to the 
pyrimidine 5-position. Bromination of hydroxypyrimidines in the pyrimidine 5-position 
does not occur by direct electrophilic attack, but instead occurs by an addition-
elimination mechanism which was first proposed in 1957 by Wang et al.84, 85 The acid-
catalyzed deprotonation of the 5-position is the rate determining step (Scheme 26).86 
 
 
Scheme 26. Mechanism of bromination of 4,6-dihroxypyrimidine (46a).84, 85 
 
Once the 4,6-dihydoxypyrimidine (46a) was brominated in the pyrimidine 5-position, the 
two hydroxy groups were exchanged with chlorine to give the required pyrimidine for the 
metal halide exchange reaction, 5-bromo-4,6-dichloropyrimidine (45a). This was done 
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using phosphorusoxychloride with dimethylaniline to increase the reaction rate (Scheme 
27) 
 
N
N
OH
Br
OH
N
N
Cl
Br
Cl
a
45a, 54 %47a  
Scheme 27. Reagents and conditions: a - dimethylaniline, POCl3, 3 hours at reflux.83 
 
 
Once 5-bromo-4,6-dichloropyrimidine (45a) was synthesised successfully, it was treated 
with n-BuLi and quenched with an iodomethane (Scheme 28) to give compound 48a in 
moderate yield. 
 
 
Scheme 28. Reagents and conditions: a = n-BuLi, THF, 30 min at -78 ºC then allowed to 
warm to r.t. after addition of electrophile over 30 min.  
 
This reaction was also repeated at – 98 ºC, but with a lower yield of compound 48a 50 %. 
This reaction proved that metal halide exchange is a method that can be used for the 
introduction of alkyl groups in the pyrimidine 5-position of 5-bromo-4,6-
dichloropyrimidine.  
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3. BIOLOGICAL DATA 
 
All compounds synthesised have been submitted for testing for antimycobacterial activity 
against Mtb by the Tuberculosis Antimicrobial Acquistion and Coordinating Facility 
(TAACF), established in 1994 by the National Institute of Allergies and Infections 
(NIAD).87 Antimycobacterial activity has been determined by in vitro screening of the 
substituents against Mtb H37RV [American type culture collection (ATCC) 27294]. With 
results being reported as minimum inhibitory concentration (MIC), where MIC is the 
amount of antimicrobial agent required to inhibit growth of the micro-organism. 
Unfortunately TAACF recently changed their testing method, where in the past they 
reported results as MIC they now report IC50 and IC90, an improvement but at the same 
time it makes it difficult to compare past results for purines which are given in MIC and 
recent pyrimidine results which are reported as IC50/90. The results are presented in Table 
11, and Figure 16 shows a general structure for the tested compounds. For comparison of 
bioreactivities for pyrimidines previously synthesised in our group see Table 12.73 
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Figure 16. Pyrimidine skeleton key for, Tables 11 and 12. 
 
 
Table 11. Biological test results for target compounds synthesised in this research 
project. 
Comp. R2 R5  X IC90  M. 
tuberculosis 
H37Rv 
(μg/mL) 
IC50 M. 
tuberculosis 
H37Rv 
(μg/mL) 
28a Cl H NH t t 
30a Cl H NCH3 t t 
31a Cl H O t t 
4a H NO2 NH 13.64 7.31 
5a H NO2 NCH3 12.75 5.71 
7a H NO2 O t t 
16a H NCH3 NH t t 
17a H NCH2CH3 NH t t 
21a H N(CH3)2 NH t t 
key: t = submitted for testing by TAACF, but test results not yet received 
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Table 12. Biological test results for previously synthesis antimycobacterial 
pyrimidines.73 
R2 R5 X MIC M. 
tuberculo
sis 
H37Rv 
(μg/mL)b 
IC90 M. 
tuberculosis 
H37Rv 
(μg/mL) 
IC50 M. 
tuberculosis 
H37Rv 
(μg/mL) 
IC50 
VERO 
cells 
(μg/mL) 
H H NH n.d. n.d. n.d. n.d. 
H H NCH3 n.d. 7.70 4.76 t 
H H O n.d. >100 >100 n.d. 
H NH2 NH n.d. n.d. n.d. n.d. 
H NH2 NCH3 n.d. 16.67 9.46 n.d. 
H NH2 O n.d. >100 >100 n.d. 
H NHCHO NH n.d. 0.56 0.22 t 
H NHCHO NCH3 n.d. >100 >100 n.d. 
H NHCHO O n.d. >100 >100 n.d. 
NO2 NHCHO NH 0.78 t t >62.5 
F NHCHO NH n.d. <0.2 <0.2 t 
Cl NHCHO NH n.d. 0.197 <0.2 t 
CF3 NHCHO NH n.d. 0.58 0.26 t 
CH3 NHCHO NH n.d. 0.33 <0.2 n.d. 
CH2CH3 NHCHO NH n.d. 0.53 0.26 n.d. 
OCH3 NHCHO NH n.d. 1.54 0.53 n.d. 
N(CH3)2 NHCHO NH n.d. 25.95 10.55 n.d. 
H NO2 NCHO n.d. 13.64 7.30 n.d. 
Key: t = Currently under testing. 
 
Using the biological test data currently available for antimycobacterial pyrimidines, it is 
possible to show a preliminary structural activity relationship for antimycobacterial 
pyrimidines (Figure 17). In the R2 position we have found that halides give the best 
bioactivity, while tertiary amines give the lowest. Currently those purines containing an 
amide in the R5 position are most active. To date the results are inconclusive for the SAR 
of substituents in the X position. Several pyrimidines under testing, currently which will 
hopefully improve our SAR knowledge of antimycobacterial pyrimidines. 
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NNR2 X
O
O
R5
o R5 = NHCHO > H, NO2, NH2
o R2 = F/Cl > Me > CF3, H > OMe >> NMe2
o X = Inconclusive at this time  
Figure 17. Current SAR knowledge of antimycobacterial pyrimidines. 
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4. FURTHER RESEARCH 
 
The results of the investigations performed within this master’s thesis have brought up 
several very interesting reactions that warrant further investigation. The Diels-Alder 
reaction which produced a very interesting molecule, namely, 4-chloro-8,10a-epoxy-
5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline (28a), for which no other 
molecules could be found in Scifinder which were similar in structure. This 
intermolecular Diels-Alder reaction resulted in a multiple fused ring system which could 
be of biological interest and warrants further investigation. Continue the synthesis of 
pyrimidines with other substituents in the pyrimidine 5-position is required to further 
improve the SAR knowledge of antimycobacterial pyrimidines. Synthesis of compound 
48a was a proof of concept, introduction of new alkyl substituents in the pyrimidine 5-
position has never been attempted in our group. Because the introduction of methyl into 
the pyrimidine 5-position is successful, future students will attempt the synthesis of, 5-
allyl-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidine-4-amine, 6-(furan-2-yl)-N-(4-
methoxybenzyl)-5-phenylpyrimidine-4-amine, and 6-(furan-2-yl)-N-(4-methoxybenzyl)-
5-methylpyrimidine-4-amine using the synthetic routes shown in Scheme 29. 
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Scheme 29. Synthesis route to 5-allyl-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidine-4-
amine, 6-(furan-2-yl)-N-(4-methoxybenzyl)-5-phenylpyrimidine-4-amine, and 6-(furan-
2-yl)-N-(4-methoxybenzyl)-5-methylpyrimidine-4-amine. 
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5. CONCLUSION 
 
Nine of the ten target molecules where successfully synthesised and sent for biological 
testing at TAACF where Antimycobacterial activity will be/has been determined by in 
vitro screening of the substituents against Mtb H37RV [American type culture collection 
(ATCC) 27294]. Currently biological test results have not been received for many of the 
synthesised target molecules, once they have been received, we will have a much better 
picture of the SAR of antimycobacterial pyrimidines. A great deal of interesting 
chemistry was found during the work herein, including, the Diels Alder reaction which 
resulting in compound 28a, substituent effect on reactivity and regioselectivity, effect of 
nucleophiles on regioselectivity and reactivity for nucleophilic aromatic substitution 
reactions, and  the use of temperature and solvent change to increase yields of wanted 
isomers. 34 previously unknown molecules have been synthesised plus 11 previously 
known compounds. The work performed within this master’s thesis has/will increase our 
knowledge of SAR of antimycobacterial pyrimidines, as well as allowing future students 
to continue the work not completed herein due to time constraints with ease due to in 
depth research discussed within this master’s thesis on the reactivity of substituted 
pyrimidines. 
Compound 28a is of particular interest; this reaction could be a very easy method of 
synthesising several new complex multi fused ring organic molecules, in only three 
reaction steps. Currently the Diels-Alder reaction which results in the formation of 
compound 28a only give 40 % yields, but this reaction has not been optimized and could 
possibly give much better yields when optimized. 
Finally a new method for the removal of organotin chloride was developed during this 
research which removes the chance for the introduction of alkoxy groups and gives 
products free of organotin chloride consistently. 
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6. EXPERIMENTAL  
 
The 1H NMR spectra were recorded at 600 MHz with a Bruker AV 600 instrument, at 
500 MHz with a Bruker Avance DRX 500 instrument, at 300 MHz with a Bruker DPX 
300 or at 200 MHz with a Bruker DPX 200 instrument.  The 13C NMR spectra were 
recorded at 150, 125, 75 or 50 MHz using the above mentioned instruments.  Mass 
spectra were on a VG Prospec sector instrument from Fissions Instruments at 70 eV 
ionizing voltage and are presented as m/z (% rel. int.). Melting points were determined 
with a C. Reichert melting point apparatus and Büchi melting point B-545 apparatus and 
are uncorrected. DMF was distilled over BaO and stored over 4 Å molecular sieves. THF 
was distilled from Na/benzophenone. All other reagents were commercially available and 
used as received. Elemental analyses were performed by Ilse Beetz Mikroanalytisches 
Laboratorium, Kronach, Germany.  
 
Due to instrument failure of the VG Prospec sector instrument from Fissions Instruments 
several MS-EI and HR-MS results are missing from this report, including compounds 
11c, 20a, 22a, 40c, 42b, 47a, and 48a. MS-EI and HR-MS results will be collected when 
the equipment is functioning again. 
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Synthesis of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a) and 
N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b) 
 
  
 
 
                5a                                                  5b 
 
A mixture of 4,6-dichloro-5-nitropyrimidine (1a) (291 mg, 1.50 mmol), 4-
methoxybenzylamine (2a) (0.13 mL, 1.0 mmol), and triethylamine (0.22 mL, 1.6 mmol) 
in dichloromethane (5 mL) was mixed at -78 °C for four hours and evaporated in vacuo. 
The residue was dissolved in dichloromethane (3 x 50 mL) and the solution was washed 
with water (2 x 50 mL), dried (MgSO4) and evaporated in vacou. The product was 
purified by flash chromatography on silica gel using dichloromethane/hexane 9/1. This 
gave 234 mg (80 %) of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a) as 
yellow crystals and 25.0 mg (7%) N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-
diamine (5b) as yellow crystals. 
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6-Cloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a) 
 
1H  NMR (CDCl3, 300 MHz): δ 8.42 (s, 1H, CH), 7.72 (bs, 1H, NH), 7.25 (d, J = 8.7 Hz, 
2H in Ar), 6.89 (d, J = 8.7 Hz, 2H in Ar), 4.73 (d, J = 5.6 Hz, 2H, CH2), 3.8 (s, 3H, 
OCH3).  
 
13C NMR (CDCl3, 75 MHz): δ 159.5 (C-4, Ar), 158 (C-2), 155.5 (C-6), 155.1 (C-4), 
129.2 (C-2, Ar), 128.4 (C-1, Ar), 126.9 (C-5), 114.3 (C-3, Ar), 55.3 (OCH3), 45.3 (CH2).  
 
MS EI m/z (rel. %): 296/294 (4/11, M+), 277 (89), 246 (100), 158 (30), 121 (76). 
 
HR-MS found 294.0513, calcd. for C12H11ClN4O3 294.052. 
 
Anal.: Found C, 48.96; H, 3.89; N, 18.91. C12H11ClN4O3 requires C, 48.91; H, 3.76; N, 
19.01. 
 
M.p. 84-86 °C from dichloromethane/hexane 9/1. 
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Spectrum 1. 1H NMR of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a). 
 
Spectrum 2. 13C NMR of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a). 
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N4,N6-Bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b) 
 
1H  NMR (DMSO-d6, 300 MHz): δ 9.75 (s, 2H, NH), 8.1 (s, 1H, CH), 7.26 (d, J = 8.7 
Hz, 4H in Ar), 6.86 (d, J = 8.7 Hz, 4H in Ar), 4.68 (d, J = 6.0 Hz, 4H, CH2), 3.71 (s, 6H, 
OCH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 159.3 (C-2), 158.3 (C-4, Ar), 156.5 (C-4), 130.6 (C-1, 
Ar), 128.8 (C-2, Ar), 113.7 (C-3, Ar), 112 (C-5), 55 (OCH3), 43.6 (CH2). 
 
MS EI m/z (rel. %): δ 396/395 (1/5, M+), 378 (45), 360 (24), 121 (100). 
 
HR-MS Found 395.1600, calcd. for C20H21N5O3 395.1594. 
 
Anal.: Found C, 60.61; H, 5.37; N, 17.64. C20H21ClN5O4 requires C, 60.75; H, 5.35; N, 
17.71. 
 
M.p. 156 – 158 °C from dichloromethane/hexane 9/1. 
 
 
Compound known in literature M.p. 152 – 153 °C from chloroform/benzene 2/3.61 
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 Spectrum 3. 1H NMR of N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b). 
 
Spectrum 4. 13C NMR of N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b). 
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Synthesis of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-amine 
(6a) 
 
                6a 
 
A mixture of 4,6-dichloro-5-nitropyrimidine (1a) (194 mg, 1.00 mmol), N-methyl-4-
methoxybenzylamine (3a) (151 mg, 1.00 mmol), and triethylamine (0.15 mL, 1.1 mmol) 
in dichloromethane (5 mL) was stirred at 0 °C for three hours and evaporated in vacou. 
The residue was dissolved in dichloromethane (3 x 50 mL) and the solution was washed 
with water (2 x 50 mL), dried (MgSO4) and evaporated in vacou. The product was 
purified by flash chromatography on silica gel using dichloromethane/hexane 9/1. This 
gave 222 mg (72 %) of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-
amine (6a) as yellow crystals. 
 
 
 
 
 
 
 
 
 
 
 
 75
1H NMR (CDCl3, 300 MHz): δ  8.37 (s, 1H, H), 7.16 (d, 2H, J = 8.7 Hz, H-2 in Ar), 6.89 
(d, 2H, J = 8.7 Hz, H-3 in Ar), 4.85 (s, 2H, CH2), 3.78  (s, 3H, OCH3), 2.86 (s, 3H, 
NCH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.9 (C-4, Ar), 156.6 (C-2), 154.8 (C-6), 153.3 (C-4), 
129.6 (C-5), 129.5 (C-2, Ar), 127.8 (C1, Ar), 114.7 (C-3, Ar), 55.7 (OCH3), 54.6 (CH2), 
36 (CH3).  
 
MS EI m/z (rel. %): 308 (0.15, M+), 172 (34), 155 (50), 121 (100). 
 
HR-MS Found 308.0664, calcd. for C13H13ClN4O3 308.0676.  
  
Anal.: Found C, 50.68; H, 4.36; N, 18.05. C13H13ClN4O3 requires C, 50.58; H, 4.24; N, 
18.15.  
 
M.p. 92-94 °C from dichloromethane/hexane 9/1. 
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Spectrum 5. 1H NMR of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-amine (6a). 
 
Spectrum 6. 13C NMR of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-amine (6a). 
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Synthesis of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a) 
N
N NH
O
NO2
O
 
                 9a 
 
A mixture of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (5a) (147 mg, 
0.50 mmol), 2-furyl(tributyl)tin (8a) (0.20 mL, 0.60 mmol) and (Ph3P)2PdCl2 (18 mg, 
0.025 mmol) in dry DMF (5 mL) was stirred at 90 oC under N2 for 16 h, and evaporated 
in vacou. KF (sat. sol. in MeOH, 10 mL) was added and the resulting mixture was stirred 
at ambient temperature for 16 h. The mixture was evaporated in vacou. The product was 
purified by flash chromatography on silica gel using ethyl acetate/hexane gradient elution 
0/1 ethyl acetate/hexane to 1/1 ethyl acetate/hexane over 30minutes, at a flow rate of 30 
mL/min. This gave 104 mg (63 %) of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-
nitropyrimidin-4-amine (9a) as brown crystals. 
 
Also synthesised by the following method: 
 
A mixture of 4-chloro-5-nitro-6-furan-2-ylpyrimidine (11a) (225 mg, 1.00 mmol) was 
dissolved in dichloromethane (10 mL). Triethylamine (0.07 mL, 0.50 mmol) was then 
added to the mixture, the mixture was cooled to -78°C. 4-Methoxybenzylamine (2a) (137 
mg, 1.00 mmol) was added to the mixture, the resulting mixture was stirred at -78°C for 
one hour. The reaction mixture was then washed with water (2 x 20 mL), dried (MgSO4) 
and evaporated in vacou. The product was purified by flash chromatography on silica gel 
using hexane/ethyl acetate 7/3. This gave 140 mg (87 %) of 2-(furan-2-yl)-N-(4-
methoxybenzyl)-5-nitropyrimidin-4-amine (9a) as yellow crystals. 
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2-(Furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a) 
 
1H NMR (DMSO-d6, 300 MHz) δ 8.52 (s, 1H, H-2), 8.49 (t, J = 5.8 Hz, 1H, NH), 7.95 
(dd, J = 1.7, 0.8 Hz, 1H, H-5 furyl), 7.32 (dd, J = 3.5, 0.8 Hz, 1H, H-3 furyl), 7.24 (d, J = 
8.7 Hz, 2H, H-2 Ar), 6.87 (d, J = 8.7 Hz, 2H, H-3 Ar), 6.73 (dd, J = 3.5, 1.7 Hz, 1H, H-4 
furyl), 4.56 (d, J = 5.8 Hz, 2H, CH2), 3.70 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 75 MHz) δ 158.3 (C-4, Ar), 158.2 (C-2), 153.3 (C-4), 148.1 (C-2, 
furyl), 147.3 (C-5, furyl), 143.9 (C-6), 130.6 (C-1, Ar), 128.6 (C-2, Ar), 126.4 (C-5), 
115.7 (C-3, furyl), 113.7 (C-3, Ar), 112.7 (C-4, furyl), 55 (CH3), 43.2 (CH2). 
 
MS EI m/z (rel. %): 327/326 (2/11, M+), 309 (100), 278 (96), 250 (22), 190 (42), 121 
(78). 
 
HR-MS found 326.1014, calcd. for C16H14N4O4 326.1015. 
 
Anal.: Found C, 58.96; H, 4.35; N, 17.05. C16H14N4O4 requires C, 58.89; H, 4.32; N, 
17.17. 
 
M.p. 118.5–119 °C from hexane/ethyl acetate 7/3. 
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Spectrum 7. 1H NMR of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a). 
 
Spectrum 8. 13C NMR of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a). 
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Synthesis of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-
amine (10a) 
N
N N
O
NO2
O
 
              10a 
 
A mixture of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-4-amine (6a) 
(132 mg, 0.428 mmol), 2-furyl(tributyl)tin (8a) (0.20 mL, 0.60 mmol) and (Ph3P)2PdCl2 
(18 mg, 0.025 mmol) in dry DMF (5 mL) was stirred at 90 oC under N2 for 16 h, and 
evaporated in vacou. KF (sat. sol. in MeOH, 10 mL) was added and the resulting mixture 
was stirred at ambient temperature for 16 h. The mixture was evaporated in vacou. The 
product was purified by flash chromatography on silica gel using ethyl acetate/hexane 
gradient elution 0/1 ethyl acetate/hexane to 1/1 over 30 minutes, at a flow rate of 
30mL/min. This gave 104 mg (63 %) of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-
5-nitropyrimidin-6-amine (10a) as brown crystals. 
 
1H NMR (CDCl3, 300 MHz): δ 8.55 (s, 1H, H-2), 7.56 (dd, J = 1.7, 0.7 Hz, 1H, H-5 Ar), 
7.26 (dd, J = 3.6, 0.7 Hz, 1H, H-3 furyl), 7.18 (d, J = 8.7 Hz, 2H, H-2 Ar), 6.86 (d, J = 
8.7 Hz, 2H, H-3 Ar), 6.53 (dd, J = 3.6, 1.7 Hz, 1H, H-4 furyl), 4.86 (s, 2H, CH2), 3.78 (s, 
3H, OCH3), 2.94 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.2 (C-4, Ar), 156.5 (C-2), 153.9 (C-4), 148 (C-2, 
furyl), 146.6 (C-6), 146 (C-5, Ar), 128.9 (C-2, Ar), 128.2 (C-1, Ar), 127.4 (C-5), 116 (C-
3 furyl), 114.2 (C-3, Ar), 112.3 (C-4, furyl), 55.3 (OCH3), 54.3 (CH2), 35 (CH3). 
 
MS EI m/z (rel. %): 340 (0.1, M+), 204 (29), 187 (100), 121 (94). 
 
HR-MS found 340.1178, calcd. for C17H16N4O4 340.1172. 
 
Anal.: Found C, 59.92; H, 4.79; N, 16.43. C17H16N4O4 requires C, 59.99; H, 4.74; N, 
16.43. 
 
M.p. 79-81 °C from ethyl acetate/hexane 1/1. 
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Spectrum 9. 1H NMR of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-amine (10a). 
 
Spectrum 10. 13C NMR of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-amine (10a). 
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Synthesis of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a) and 4,5-di(furan-2-yl)-
5-nitropyrimidine (11b) 
  
             11a                                  11b 
 
A mixture of 4,6-dichloro-5-nitropyrimidine (1a) (380 mg, 2.00 mmol), 2-
furyl(tributyl)tin (8a) (0.33 mL, 1.0 mmol) and (Ph3P)2PdCl2 (35 mg, 0.05 mmol) in dry 
THF (5 mL) was stirred at r.t. under N2 for 16 h, and evaporated in vacou. KF (sat. sol. in 
THF, 50 mL) was added and the resulting mixture was stirred at ambient temperature for 
16 h. The mixture was evaporated in vacou. The product was purified by quick flash 
chromatography on a short column of silica gel using acetone/hexane 1/3. KF (sat. sol. in 
THF, 50 mL) was added and the resulting mixture was stirred at ambient temperature for 
16 h. The mixture was evaporated in vacou. The product was purified by flash 
chromatography on silica gel using hexane/ethyl acetate 17/3. This gave 165 mg (73 %) 
of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a) as a yellow power and 60 mg (20 %) 
of 4,5-di(furan-2-yl)-5-nitropyrimidine (11b) as a yellow oil, and 100 mg (26 %) of the 
starting material 4,6-dichloro-5-nitropyrimidine. 
 
4-Chloro-6-(furan-2-yl)-5-nitropyrimidine (11a) 
 
1H NMR (CDCl3, 300 MHz): δ 8.92 (s, 1H, H-2), 7.66 (dd, J = 1.7, 0.7 Hz, 1H, H-5 
furyl), 7.51 (dd, J = 3.7, 0.7 Hz, 1H, H-3 furyl), 6.64 (dd, J = 3.7, 1.7 Hz , 1H, H-4 furyl). 
 
13C NMR (CDCl3, 75 MHz): δ 157.7 (C-2), 152.8 (C-4), 148.2 (C-5, furyl), 147 (C-2, 
furyl or C-6), 146.6 (C-2, furyl or C-6), 138.3 (C-5), 118.7 (C-3, furyl), 113.3 (C-4, 
furyl). 
 
MS EI m/z (rel. %): 227/225 (7/21, M+), 190 (20), 180 (28), 83 (100), 68 (4). 
 
HR-MS Found 224.9935, calcd. for C8H4ClN3O3 224.9941. 
 
M.p. 110 – 111 °C from hexane/ethyl acetate 17/3. 
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Spectrum 11. 1H NMR of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a). 
 
Spectrum 12. 13C NMR of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a). 
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4,5-Di(furan-2-yl)-5-nitropyrimidine (11b) 
 
1H NMR (CDCl3, 300 MHz): δ 9.04 (1H, H-2), 7.65 (dd, J = 1.7, 0.8 Hz, 2H, H-5 furyl), 
7.42 (dd, J = 3.6, 0.8 Hz, 2H, H-3 furyl), 6.60 (dd, J = 3.6, 1.7 Hz, 2H, H-4 furyl). 
 
13C NMR (CDCl3, 75 MHz): δ 157.9 (C-2), 147.8 (C-2, furyl), 147.3 (C-5, furyl), 146.5 
(C-4), 117.3 (C-3, furyl), 112.9 (C-4, furyl), C-5 not visible. 
 
MS EI m/z (rel. %): 258/257 (5/33, M+), 212 (6), 201 (18), 147 (18), 83 (100). 
 
HR-MS Found 257.0434, calcd. for C12H7N3O4 257.0437. 
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Spectrum 13. 1H NMR of 4,5-di(furan-2-yl)-5-nitropyrimidine (11b). 
 
Spectrum 14. 13C NMR of 4,5-di(furan-2-yl)-5-nitropyrimidine (11b). 
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Synthesis of 4-(furan-2-yl)-6-methoxy-5-nitropyrimidine (11c)  
 
 
               11c 
 
A mixture of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a) (100 mg, 0.45 mmol) in 
methanol (50 mL) was stirred for 24 hrs. at r.t. the reaction mixture was evaporated in 
vacou, then dissolved in dichloromethane, washed (H2O 2 x 100 mL), and dried 
(MgSO4). The reaction mixture was then evaporated in vacou to give 97 mg (98 %) 4-
(furan-2-yl)-6-methoxy-5-nitropyrimidine (6c) as a colourless powder. 
 
 
1H NMR 1H NMR (CDCl3, 300 MHz,): δ 8.70 (s, 1H, H-2), 7.60 (dd, J = 0.8, 1.7, 1H, H-
5 furyl), 7.35 (dd, J = 0.8, 3.6, 1H, H-3 furyl), 6.58 (dd, J = 1.7, 3.6, 1H, H-4 furyl), 4.10 
(s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 161.4 (C-4), 157.6 (C-2), 147.7 (C-2 furyl), 147.0 (C-5 
furyl), 145.4 (C-6), 116.7 (C-3 furyl), 112.7 (C-4 furyl), 55.4 (CH3), C-5 not seen. 
. 
 
MS EI m/z (rel. %): waiting on results 
 
HR-MS waiting on results 
 
M.p. 100 – 102 °C from dichloromethane. 
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Spectrum 15. 1H NMR of 4-(furan-2-yl)-6-methoxy-5-nitropyrimidine (11c) 
 
Spectrum 16. 13C NMR of 4-(furan-2-yl)-6-methoxy-5-nitropyrimidine (11c) 
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Synthesis of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a) 
 
                12a 
 
A solution of p-methoxybenzyl alcohol (4a) (100 mg, 0.70 mmol) in dry THF (5.0 mL) 
was added over 5 min to a stirring suspension of sodium hydride (32 mg, ca. 65% in oil, 
ca 0.70 mmol) in dry THF (5 mL) under N2 at r.t. The resulting mixture was stirred at r.t. 
under N2 for 1 hour and cooled to 0 oC before the 4-chloro-6-(furan-2-yl)-5-
nitropyrimidine (6a)  (110 mg, 0.50 mmol) in THF (5 mL) was added over 15 min. The 
resulting mixture was stirred at r.t. for 3.5 hours. Sat aq. NH4Cl (10 mL) was added and 
the mixture was extracted with CH2Cl2 (4 × 15 mL).The combined organic extracts were 
washed with sat. aq. NaCl (15 mL), dried (MgSO4) and evaporated in vacou. The product 
was purified by flash chromatography on silica gel using hexane/ethyl acetate 9/1. This 
gave 168 mg (91 %) of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a) 
as a colourless powder. 
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1H NMR (CDCl3, 300 MHz): δ 8.61 (s, 1H, H-2), 7.53 – 7.48 (m, 1H, H-5 furyl), 7.31 – 
7.21 (m, 3H, H-3 Ar and H-3 furyl), 6.80 (d, J = 8.7 Hz, 2H, H-2 Ar), 6.48 (dd, J = 3.6, 
1.7 Hz, 1H, H-4 furyl), 5.39 (s, 2H, CH2), 3.70 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 160.8 (C-4), 159.9 (C-6), 157.4 (C-2), 147.7 (C-2, furyl), 
146.9 (C-5, furyl), 145.4 (C-4, Ar), 130 (C-3, Ar), 128.8 (C-5), 126.7 (C-1, Ar), 116.6 
(C-3, furyl), 114 (C-2, Ar), 112.6 (C-4, furyl), 69.7 (CH2), 55.2 (CH3). 
 
MS EI m/z (rel. %): 327 (1, M+), 191 (15), 121 (100), 91 (5). 
 
HR-MS Found 327.0859, calcd. for C16H13N3O5 327.0855. 
 
Anal.: Found C, 58.80; H, 4.07; N, 12.78. C16H13N3O5 requires C, 58.72; H, 4.0; N, 
12.84. 
 
M.p. 118.8 – 120.4 °C from hexane/ethyl acetate 9/1. 
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Spectrum 17. 1H NMR of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a). 
 
Spectrum 18. 13C NMR of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a). 
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Synthesis of 4,6-dichloro-N-methylpyrimidin-5-amine (14a) 
 
        14a 
 
A solution of 5-amino-4,6-dichloropyrimidine (13a) (0.98 g, 6.00 mmol) in THF (15 mL) 
was treated with 65 % NaH (260 mg, ca. 7.00 mmol) in THF (10 mL) at 0 ºC then the 
mixture was allowed to warm to r.t. and stirred for 20 minutes under N2. Then 
iodomethane (1.00 g, 7.00 mmol) and tetrabutylammonium bromide (2.25 g, 7.00 mmol) 
were added. The mixture was stirred for 2 hours at r.t, concentrated in vacou and purified 
by flash chromatography on silica gel using hexane/ethyl acetate 8/1. This gave 808 mg 
(76 %) of 4,6-dichloro-N-methylpyrimidin-5-amine (14a) as colourless crystals. 
 
1H NMR (CDCl3, 300 MHz): δ 8.18 (s, 1H, H-2), 4.05 (bs, 1H, NH), 3.14 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 147.8 (C-4/C-6), 147.2 (C-2), 139.1 (C-5), 34.1 (CH3). 
 
MS EI m/z (rel. %): 181/179/177 (10/64/100, M+), 140 (27) 100 (7), 79 (12). 
 
HR-MS Found 176.9854, calcd. for C5H5Cl2N3 176.9861. 
 
M.p. 81.9 – 82.0 °C from hexane/ethyl acetate 8/1. 
 
Compound known in literature.81 
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Spectrum 19. 1H NMR of 4,6-dichloro-N-methylpyrimidin-5-amine (14a). 
 
Spectrum 20. 13C NMR of 4,6-dichloro-N-methylpyrimidin-5-amine (14a). 
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Synthesis of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a) 
 
          15a 
 
A solution of 5-amino-4,6-dichloropyrimidine (13a) (820 mg, 5.00 mmol) in THF (15 
mL) was treated with 65 % NaH (220 mg, 6.00 mmol) in THF (10 mL) at 0 °C. The 
mixture was allowed to warm to r.t. and stirred for 20 minutes under N2. Then iodoethane 
(936 mg, 6.00 mmol) and tetrabutylammonium bromide (TBAB) (1.93 g, 6.00 mmol) 
were added. The mixture was stirred for 2 hours and concentrated in vacou and purified 
by flash chromatography on silica gel using hexane/ethyl acetate 17/3. This gave 740 mg 
(77 %) of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a) as colourless crystals. 
 
1H NMR (CDCl3, 300MHz): δ 8.26 (s, 1H, H-2) 4.04 (bs, 1H, NH), 3.55 (q, J = 7.2 Hz, 
2H, CH2), 1.27 (t, J = 7.2 Hz, 3Η, CH3). 
 
13C NMR (CDCl3, 75MHz): δ 148.8 (C4), 147.6 (C2) 138.3 (C5), 41.8 (CH2), 16.7 
(CH3). 
 
MS EI m/z (rel. %): 195/193/191 (3/17/26, M+), 176 (100). 
 
HR-MS found, 191.0021 calcd. for C6H7Cl2N3 191.0017. 
 
M.p. 53 – 54 ºC from hexane/ethyl acetate 17/3. 
 
Compound known in literature.64 
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Spectrum 21. 1H NMR of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a). 
 
Spectrum 22. 13C NMR of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a). 
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Synthesis of N-Allyl-4,6-dichloropyrimidin-5-amine (16a) 
N
N
Cl
NH
Cl
 
         16a 
 
A solution of 5-amino-4,6-dichloropyrimidine (13a) (656 mg, 4.00 mmol) in THF (5 mL) 
was treated with 65 % NaH (220 mg, 6.00 mmol) in THF (5 mL) at 0 °C then the mixture 
was allowed to warm to room temperature and stirred for 20 minutes under nitrogen. 
Then allyl bromide (720 mg, 6.00 mmol) and TBAB (1.9 g, 6.00 mmol) were added. The 
mixture was stirred for 2 hours, concentrated in vacou and purified by flash 
chromatography on silica gel using hexane/ethyl acetate 17/3. This gave 510 mg (65 %) 
of N-Allyl-4,6-dichloropyrimidin-5-amine (16a) as a colourless oil. 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.25 (s, 1H, H-2), 6.07 – 5.55 (m, 2H, CH and NH), 
5.28 – 4.93 (m, 2H, CH2 vinyl), 4.03 (tt, J = 5.6, 1.5 Hz , 2H, CH2).  
 
13C NMR (DMSO-d6, 75 MHz): δ 147.6 (C-4/C-6), 146.7 (C-2), 137.4 (C-5), 136 (CH), 
116.2 (CH2, vinyl), 47.1 (CH2). 
 
MS EI m/z (rel. %): 207/205/203 (4/20/32, M+), 168 (80), 41 (100).   
 
HR-MS found, 203.0011 calcd. for C7H7Cl2N3 203.0017. 
 
Compound known in literature.64 
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Spectrum 23. 1H NMR of N-Allyl-4,6-dichloropyrimidin-5-amine (16a). 
 
Spectrum 24. 13C NMR of N-Allyl-4,6-dichloropyrimidin-5-amine (16a). 
 
 
Synthesis of 6-chloro-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (17a) 
 97
NN
Cl
NH
NH
O
 
        17a 
 
Triethylamine (1.74 mL, 12.6 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (440 mg, 3.20 mmol) in n-butanol (15 mL). After 
stirring for ten minutes, 4,6-dichloro-N-methylpyrimidine-5-amine (14a) (531 mg, 3.00 
mmol) was added. The reaction mixture was stirred for 40 hours at 100 ºC then cooled to 
r.t., evaporated in vacou and purified by flash chromatography on silica gel using 
hexane/acetone 7/2. This gave 750 mg (90 %) of 6-chloro-N4-(4-methoxybenzyl)-N5-
methylpyrimidine-4,5-diamine (17a) as a colourless oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.20 (s, 1H, H-2), 7.28 (d, J = 8.6 Hz, 2H, H-2 Ar), 6.89 
(d, J = 8.6 Hz, 2H, H-3 Ar), 5.95 (s, 1H, NH), 4.63 (d, J = 5.7 Hz, 2H, CH2), 3.87 (s, 3H, 
OCH3), 3.04 (bs, 1H, NH), 2.64 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.1 (C-4 or C-4 Ar), 158.9 (C-4 or C-4 Ar), 153.2 (C-
2), 150.6 (C-6), 130.3 (C-1 Ar), 129 (C-2 Ar), 124.4 (C-5), 114.1 (C-3 Ar), 55.3 (OCH3), 
44.6 (CH2), 33.6 (CH3). 
 
MS EI m/z (rel. %): 280/278 (5/15, M+), 121 (100), 78 (5). 
 
HR-MS Found 278.0936, calcd. for C13H15ClN4O 278.0934. 
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Spectrum 25. 1H NMR of 6-chloro-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (17a). 
 
Spectrum 26. 13C NMR of 6-chloro-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (17a). 
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Synthesis of 6-chloro-N5-ethyl-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (18a) 
N
N
Cl
NH
NH
O
 
           18a 
 
Triethylamine (1.12 mL, 8.00 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (274 mg, 2.00 mmol) in n-butanol (15 mL). After 
stirring for ten minutes, 4,6-dichloro-N-ethylpyrimidine-5-amine (15a) (382 mg, 2.00 
mmol) was added. The reaction mixture was stirred for 19 hours at 100 ºC then cooled to 
r.t., evaporated in vacou and purified by flash chromatography on silica gel using 
hexane/acetone 7/2. This gave 533 mg (91 %) of 6-chloro-N5-ethyl-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (18a) as a yellow oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.17 (s, 1H, H-2), 7.36 – 7.09 (m, 2H, H-2 Ar), 6.86 (d, J 
= 8.7 Hz, 2H, H-3 Ar), 5.89 (s, 1H, NH), 4.59 (d, J = 5.7 Hz, 2H, CH2-Ar), 3.78 (s, 3H, 
OCH3), 3.33 – 3.02 (bs, 1H, NH), 2.89 (q, J = 7.2 Hz, 2H, CH2), 1.15 (t, J = 7.2 Hz, 3H, 
CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.1 (C-4 or C-4, Ar), 159 (C-4 or C-4, Ar), 153.1 (C-2), 
150.8 (C-6), 130.3 (C-1, Ar), 128.9 (C-2, Ar), 123.2 (C-5), 114.2 (C-3, Ar), 55.3 (OCH3), 
44.7 (CH2, Ar), 41.9 (CH2), 15.9 (CH3). 
 
MS EI m/z (rel. %): 294/292 (6/18, M+), 171 (8), 121 (100). 
 
HR-MS Found 292.1084, calcd. for C14H17ClN4O 292.1091. 
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Spectrum 27. 1H NMR of 6-chloro-N5-ethyl-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (18a). 
 
Spectrum 28. 13C NMR of 6-chloro-N5-ethyl-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (18a). 
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Synthesis of N5-allyl-6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (19a) 
N
N
Cl
NH
NH
O
 
       19a 
 
Triethylamine (1.12 mL, 8.00 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (260 mg, 1.90 mmol) in n-butanol (15 mL). After 
stirring for ten minutes, N-allyl-4,6-dichloropyrimidine-5-amine (16a) (389 mg, 1.90 
mmol) was added. The reaction mixture was stirred for 24 hours at 100 ºC then cooled to 
r.t. The reaction mixture was evaporated in vacou and purified by flash chromatography 
on silica gel using hexane/acetone 7/2. This gave 255 mg (45 %) of N5-allyl-6-chloro-N4-
(4-methoxybenzyl)pyrimidine-4,5-diamine (19a) as a yellow oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.11 (s, 1H, H-2), 7.18 (d, J = 8.7 Hz, 2H, H-2 Ar), 6.8 
(d, J = 8.7 Hz, 2H, H-3 Ar), 5.96 – 5.70 (m, 2H, CH vinylic and NH), 5.12 (ddd, J = 13.6, 
11.5, 1.4 Hz, 2H, CH2 vinylic), 4.54 (d, J = 5.7 Hz, 2H, CH2), 3.73 (s, 3H, CH3), 3.49 – 
3.34 (m, 2H, CH2 attached to vinyl), 2.90 (bs, 1H, NH). 
 
13C NMR (CDCl3, 75 MHz): δ 159.1 (C-4, Ar or C-4), 158.9 (C-4, Ar or C-4), 153 (C-2), 
150.7 (C-6), 135.1 (CH, vinylic), 130.3 (C-1), 128.9 (C-2, Ar), 123 (C-5), 117.3 (CH2, 
vinylic), 114.1 (C-3, Ar), 55.3 (CH3), 49.4 (CH2, vinylic), 44.7 (CH2). 
 
MS EI m/z (rel. %): 306/304 (7/22, M+), 263 (30), 183 (14) 121 (100), 78 (9). 
 
HR-MS Found 304.1089, calcd. for C15H17ClN4O 304.1091.  
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Spectrum 29. 1H NMR of N5-allyl-6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (19a). 
 
Spectrum 30. 13C NMR of N5-allyl-6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (19a). 
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Synthesis of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a) 
N
N
NH
Cl
O
 
       20a 
 
A mixture of tris(diphenylmethyllideacetone)dipalladium (27 mg, 0.03 mmol) and tri(2-
furyl)phosphine (51 mg, 0.22 mmol) was weighed out into a flask. DMF (10 mL) was 
added and the flask flushed with N2. The mixture was stirred for 30 min at r.t. 4,6-
Dichloro-N-methylpyrimidin-5-amine (14a) (180 mg, 1.00 mmol)  was added to 5 mL 
DMF under N2  and this mixture added to the first mixture. Followed by the addition of 
2-furyl(tributyl)tin (8a) (0.350 mL,  1.1 mmol). The mixture was then stirred over night 
at 70 °C (16 hrs) and evaporated in vacou. sat. aq. KF in methanol 30 mL was added, the 
reaction mixture stirred for a further 16 hrs. and then evaporated in vacou. The product 
was purified by flash chromatography on silica gel using hexane/ethyl acetate 7/3. This 
gave 70 mg (30 %) of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a) as a 
yellow oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.41 (s, 1H, H-2), 7.57 (dd, J = 1.8, 0.7 Hz, 1H, H-5 
furyl), 7.22 (dd, J = 3.5, 0.7 Hz, 1H, H-3 furyl), 6.54 (dd, J = 3.5, 1.8 Hz, 1H, H-4 furyl), 
4.53 (bs, 1H, NH), 2.84 (s, 3H, CH3).  
 
13C NMR (CDCl3, 75 MHz): δ 152 (C-4), 150.6 (C-2, furyl), 149.3 (C-2), 145 (C-6), 
144.3 (C-5, furyl), 137.2 (C-5), 114.7 (C-3, furyl), 112.2 (C-4, furyl), 34.1 (CH3) 
 
MS EI m/z (rel. %): waiting on results. 
 
HR-MS waiting on results. 
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Spectrum 31. 1H NMR of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a). 
 
Spectrum 32. 13C NMR of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a). 
 
 
 105
Synthesis of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a) 
N
N
NH
Cl
O
 
      21a 
 
A mixture of tris(diphenylmethylideacetone)dipalladium (27 mg, 0.03 mmol) and tri(2-
furyl)phosphine (51 mg, 0.22 mmol) was weighed out into a flask. DMF (5 mL) was 
added and the flask flushed with N2. The mixture was stirred for 30 min at r.t. 4,6-
Dichloro-N-ethylpyrimidin-5-amine (15a) (191 mg, 1.00 mmol)  was added to DMF (5 
mL) under N2  and this mixture added to the first mixture. Followed by the addition of 2-
furyl(tributyl)tin (8a) (0.35 mL, 1.1 mmol), the resulting mixture was then stirred over 
night at 80°C (16 hrs), then evaporated in vacou. sat. aq. KF in MeOH (30 mL) was 
added and the mixture stirred for a further 16 hrs, then evaporated in vacou. The product 
was purified by flash chromatography on silica gel using hexane/acetone 9/1. This gave 
85 mg (38 %) of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a) as a brown oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.46 (s, 1H, H-2), 7.60 (dd, J = 1.7, 0.7 Hz, 1H, H-5 
furyl), 7.29 (dd, J = 3.5, 0.7 Hz, 1H, H-3 furyl), 6.57 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 
4.06 (bs, 1H, NH), 3.16 (q, J = 7.2 Hz, 2H, CH2), 1.17 (t, J = 7.2 Hz, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 153 (C-4), 150.7 (C-2, furyl), 149.7 (C-2), 145.9 (C-6), 
144.4 (C-5, furyl), 136 (C-5), 114.9 (C-3, furyl), 112.3 (C-4, furyl), 42.1 (CH2), 16 
(CH3). 
 
MS EI m/z (rel. %): 225/223 (90/30, M+), 208 (33), 194 (40), 180 (100), 144 (14). 
 
HR-MS Found 223.0515, calcd. for C10H10ClN3O 223.0512.  
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Spectrum 33. 1H NMR of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a). 
 
Spectrum 34. 13C NMR of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a). 
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Synthesis of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine 
(22a) 
 
        22a 
 
Triethylamine (0.12 mL, 0.80 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (104 mg, 0.76 mmol) in n-butanol (10 mL). After 
stirring for ten minutes, 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a) (80 
mg, 0.38 mmol) was added. The reaction mixture was stirred for 24 hours at 100 ºC then 
cooled to room temperature, evaporated in vacou and purified by flash chromatography 
on silica gel using dichloromethane/hexane/ethyl acetate 7/2/1. This gave 90 mg (76 %) 
of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a) as a 
brown oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.32 (s, 1H, H-2), 7.51 – 7.45 (m, 1H, H-5 furyl), 7.21 (d, 
J = 8.7 Hz, 2H, H-2 Ar), 7.12 (dd, J = 3.5, 0.4 Hz, 1H, H-3 furyl), 6.81 (d, J = 8.7 Hz, 
2H, H-3 Ar), 6.49 (dd, J = 3.5, 1.8 Hz, 1H, H-4 furyl), 6.02 (bs, 1H, NH), 4.57 (d, J = 5.7 
Hz, 2H, CH2), 3.72 (s, 4H, OCH3 and NH), 2.57 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.6 (C-4), 158.9 (C-4, Ar), 153.6 (C-2), 153 (C-2, 
furyl), 143.4 (C-5, furyl), 143 (C-6), 130.8 (C-1), 128.9 (C-2, Ar), 123.8 (C-5), 114 (C-3 
Ar), 112 (C-4, furyl or C-3, furyl), 111.9 (C-4, furyl or C-3, furyl), 55.2 (OCH3), 44.4 
(CH2), 34.6 (CH3). 
 
MS EI m/z (rel. %): waiting for results. 
 
HR-MS waiting for results. 
 
Anal.: Found C, 66.02; H, 5.89; N, 18.07. C17H18N4O2 requires C, 65.79; H, 5.85; N, 
18.05. 
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Spectrum 35. 1H NMR of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a). 
 
Spectrum 36. 1H NMR of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a). 
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Synthesis of N5-ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(23a) 
 
        23a 
 
Triethylamine (0.06 mL, 0.40 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (37 mg, 0.27 mmol) in n-butanol (10 mL). After 
stirring for ten minutes, 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a) (60 mg, 
0.27 mmol) was added. The reaction mixture was stirred for 24 hours at 100 ºC, cooled to 
r.t., evaporated in vacou and purified by flash chromatography on silica gel using 
dichloromethane/hexane/ethyl acetate 14/5/1. This gave 60 mg (69 %) of N5-ethyl-6-
(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a) as a yellow oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.32 (s, 1H, H-2), 7.48 (dd, J = 1.7, 0.7 Hz, 1H, H-5 
furyl), 7.20 (d, J = 8.7 Hz, 2H, H-2 Ar), 7.10 (dd, J = 3.5, 0.7 Hz, 1H, H-3 furyl), 6.81 (d, 
J = 8.7 Hz, 2H, H-3 Ar), 6.49 (dd, J = 3.5, 1.7 Hz, 1H, H-4 Ar), 5.99 (s, 1H, NH), 4.56 
(d, J = 5.7 Hz, 2H, CH2-Ar), 3.86 (s, 1H, NH), 3.72 (s, 3H, OCH3), 2.82 (q, J = 7.2 Hz, 
2H, CH2), 1.06 (t, J = 7.2 Hz, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 159.8 (C-4), 158.9 (C-4, Ar), 153.6 (C-2), 153.3 (C-2 
furyl), 143.4 (C-6), 143.2 (C-5, furyl), 130.9 (C-1), 128.8 (C-2, Ar), 122.6 (C-5), 114 (C-
3, Ar), 111.9 (C-3, furyl or C-4, furyl), 111.9 (C-3, furyl or C-4, furyl), 55.3 (OCH3), 
44.4 (CH2, Ar), 42.5 (CH2), 15.7 (CH3). 
 
MS EI m/z (rel. %): 324 (58, M+), 295 (16), 203 (36), 175 (11), 121 (100), 78 (6). 
 
HR-MS Found 324.1584, calcd. for C20H22N2O2 324.1586. 
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Spectrum 37. 1H NMR of N5-ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a). 
 
Spectrum 38. 13C NMR of N5-ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a). 
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Synthesis of 4-chloro-6-(furan-2-yl)pyrimidin-5-amine (24a) and 4,6-di(furan-2-
yl)pyrimidin-5-amine (24b) 
 
            
             24a                                   24b 
 
A mixture of tris(dibenzylideneacetone)dipalladium chloroform complex (135 mg, 0.15 
mmol) and tri(2-furyl)phosphine (246 mg, 0.49 mmol) was weighed out into a flask. 
DMF (15 mL) was added and the flask flushed with N2. The mixture was stirred for 30 
min at r.t., 4,6-dichloropyrimidin-5-amine (13a)  (800 mg, 4.90 mmol)  was added to 
DMF (15 mL) under N2,  and this mixture added to the first mixture, followed by the 
addition of 2-furyl(tributyl)tin (8a) (1.60 mL,  4.90 mmol). The mixture was then stirred 
over night at 70°C (16 hrs) and evaporated in vacou. sat. sol. KF in methanol (30 mL) 
was added and the reaction mixture stirred for a further 16 hrs., then evaporated in vacou. 
The products were purified by flash chromatography on silica gel using 
dichloromethane/hexane/ethyl acetate 16/4/1. This gave 260 mg (27 %) of 4-chloro-6-
(furan-2-yl)pyrimidin-5-amine (24a) as a yellow powder and 200 mg (36 %) of 4,6-
di(furan-2-yl)pyrimidin-5-amine (24b) as a brown powder. 
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4-Chloro-6-(furan-2-yl)pyrimidin-5-amine (24a) 
 
1H NMR (CDCl3, 300 MHz): δ 8.22 (s, 1H, H-2), 7.53 (dd, J = 1.8, 0.8 Hz, 1H, H-5 
furyl), 7.19 (dd, J = 3.6, 0.8 Hz, 1H, H-3 furyl), 6.51 (dd, J = 3.6, 1.8 Hz, 1H, H-4 furyl), 
5.07 (s, 2H, NH2). 
 
13C NMR (CDCl3, 75 MHz): δ 152.3 (C-2, furyl), 146.7 (C-5), 146.4 (C-2, furyl), 143.8 
(C-5, furyl), 138.5 (C-6), 133.1 (C-4), 112.8 (C-3, furyl), 112.2 (C-4, furyl). 
 
MS EI m/z (rel. %): 197/195 (33/100, M+), 166 (32), 160 (3), 130 (25), 106 (15), 77 (8). 
 
HR-MS Found 195.0203, calcd. for C8H6ClN3O 195.0199. 
 
Anal.: Found C, 49.00; H, 3.14, N, 21.32. C8H6ClN3O requires C, 49.12; H, 3.09, N, 
21.48. 
 
M.p., 100 – 101 oC from dichloromethane/hexane/ethyl acetate 16/4/1. 
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Spectrum 39. 1H NMR of 4-chloro-6-(furan-2-yl)pyrimidin-5-amine (24a). 
 
 
Spectrum 40. 13C NMR of 4-chloro-6-(furan-2-yl)pyrimidin-5-amine (24a). 
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4,6-Di(furan-2-yl)pyrimidin-5-amine (24b) 
 
1H NMR (CDCl3, 300 MHz): δ 8.54 (s, 1H, H-2), 7.61 (dd, J = 1.7, 0.7 Hz, 2H, H-5 
furyl), 7.29 (dd, J = 3.5, 0.7 Hz, 2H, H-3 furyl), 6.59 (dd, J = 3.5, 1.7 Hz, 2H, H-4 furyl), 
5.73 (s, 2H, NH2). 
 
13C NMR (CDCl3, 75 MHz): δ 153.2 (C-2 furyl), 147.4 (C-2), 143.6 (C-5 furyl), 140.4 
(C-4), 132.3 (C-5), 112.5 (C-3 furyl), 112.1 (C-4 furyl). 
 
MS EI m/z (rel. %): 227 (100, M+), 198 (39), 170 (18), 78 (7). 
 
HR-MS Found 227.0699, calcd. for C12H9N3O2 227.0695. 
 
M.p., 91 – 92 oC from dichloromethane/hexane/ethyl acetate 16/4/1. 
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Spectrum 41. 1H NMR of 4,6-di(furan-2-yl)pyrimidin-5-amine (24b). 
 
Spectrum 42. 13C NMR of 4,6-di(furan-2-yl)pyrimidin-5-amine (24b). 
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Synthesis of 4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a) 
 
         25a 
 
A solution of 4-chloro-6-(furan-2-yl)pyrimidine-5-amine (24a) (150 mg, 0.80 mmol) in 
THF (10 mL) was treated with 65 % NaH (100 mg, 2.50 mmol) in THF (15 mL) at 0 °C 
then the mixture was allowed to warm to r.t. and stirred for 20 minutes under nitrogen. 
Then iodomethane (0.22 mL, 2.40 mmol) and TBAB (800 mg, 2.5 mmol) where added. 
The mixture was stirred for 2 hours at r.t., concentrated in vacou and purified by flash 
chromatography on silica gel using hexane/ethyl acetate 4/1. This gave 80 mg (45 %) of 
4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a) as a yellow oil. 
 
 
1H NMR (CDCl3, 300MHz): δ 8.67 (s, 1H, H-2), 7.61 (dd, J = 1.8, 0.7 Hz, 1H, H-4 
furyl), 7.41 (dd, J = 3.5, 0.7 Hz, 1H, H-2 furyl), 6.54 (dd, J = 3.5, 1.8 Hz, 1H, H-3 furyl), 
2.77 (s, 6H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 161.6 (C-4 or C-6), 155.2 (C-4 or C-6), 154.4 (C-2), 
149.1 (C-2, furyl), 145.5 (C-4, furyl), 138.6 (C-5), 117.9 (C-2, furyl), 112.8 (C-3), 41.2 
(CH3). 
 
MS EI m/z (rel. %): 225/223 (25/72, M+), 208 (12), 194 (100), 180 (22), 167 (11), 132 
(14).  
 
HR-MS found, 223.0511 calcd. for C10H10ClN3O 223.0512. 
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Spectrum 43. 1H NMR of 4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a). 
 
Spectrum 44. 1H NMR of 4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a). 
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Synthesis of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a) 
 
          26a 
 
A solution of 4-chloro-6-(furan-2-yl)pyrimidine-5-amine (24a) (150 mg, 0.80 mmol) in 
THF (10 mL) was treated with 65 % NaH (32 mg, 0.80 mmol) in THF (10 mL) at 0 °C, 
the mixture was allowed to warm to r.t. and stirred for 20 minutes under N2. Then allyl 
bromide (100 mg, 0.80 mmol) and tetrabutylammonium bromide (260 mg, 0.80 mmol) 
were added. The mixture was stirred for 2 hours, concentrated in vacou and purified by 
flash chromatography on silica gel using hexane/ethyl acetate 17/3. This gave 120 mg 
(64%) of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a) as a yellow oil. 
 
1H NMR (CDCl3, 300 MHz): δ 8.51 (s, 1H, H-2), 7.63 (dd, J = 1.8, 0.8 Hz, 1H, H-5 
furyl), 7.36 (dd, J = 3.5, 0.8 Hz, 1H, H-3 furyl), 6.60 (dd, J = 3.5, 1.8 Hz, 1H, H-4 furyl), 
5.88 (ddt, J = 17.0, 10.2, 5.9 Hz, 1H, CH), 5.18 (ddq, J = 21.8, 10.2, 1.4 Hz, 2H, CH2 
vinylic), 4.22 (bs, 1H, NH), 3.76 (dt, J = 5.9, 1.4 Hz, 2H, CH2). 
 
13C NMR (CDCl3, 75 MHz): δ 153.4 (C-4 or C-6), 150.4 (C-2, furyl), 150 (C-2), 146 (C-
4 or C-6), 144.7 (C-5, furyl), 135.7 (C-5), 134.9 (CH), 117.2 (CH2, vinylic), 115.3 (C-3, 
furyl), 112.5 (C-4, furyl), 49.7 (CH2). 
 
MS EI m/z (rel. %): 235 (100, M+), 218 (45), 206 (84), 191 (22), 179 (17). 
 
HR-MS Found 235.0519, calcd. for C11H10ClN3O 235.0512. 
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Spectrum 45. 1H NMR of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a). 
 
Spectrum 46. 13C NMR of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a). 
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Synthesis of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-
diamine (27a) 
N
N
N
NH
O
O
 
         27a 
 
Triethylamine (0.25 mL, 0.70 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (8a) (62 mg, 0.45 mmol) in n-butanol (10 mL). After 
stirring for ten minutes at room temp, 4-chloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-
amine (25a) (100 mg, 0.45 mmol) was added. The reaction mixture was stirred for 24 
hours at 100 ºC then cooled to r.t., evaporated in vacou and purified by flash 
chromatography on silica gel using hexane/ethyl acetate 3/2. This gave 29 mg (21 %) of 
6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine (27a) as a 
colourless powder. 
 
1NMR (CDCl3, 300 MHz): δ 8.43 (s, 1H, H-2), 7.60 (dd, J = 1.7, 0.8 Hz, 1H, H-5 furyl)), 
7.25 (d, J = 8.7 Hz, 2H, H-3 Ar), 7.16 (d, J = 3.0 Hz, 1H, H-3 furyl), 6.87 (d, J = 8.7 Hz, 
2H, H-3 Ar), 6.56 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 6.47 (s, 1H, NH), 4.62 (d, J = 5.8 
Hz, 2H, CH2), 3.79 (s, 3H, OCH3), 2.66 (s, 6H, CH3 x 2).  
 
13C NMR (CDCl3, 75 MHz): δ 162.1 (C-4, Ar), 159.5 (C-4), 154.4 (C-2), 150.6 (C-2 
furyl), 147.3 (C-6), 144.4 (C-5, furyl), 131.1 (C-1, Ar), 129.3 (C-3, Ar), 126.7 (C-5), 
114.6 (C-3, Ar), 113.7 (C-3, furyl), 112.6 (C-4, furyl), 55.7 (OCH3), 44.9 (CH2), 42.1 
(CH3). 
 
MS EI m/z (rel. %): 324 (100, M+), 280 (8), 203 (80), 175 (35), 121 (90), 91 (5). 
 
HR-MS Found 324.1590 calcd. for C18H20N4O2 324.1586. 
 
M.p. 91 – 92 oC from hexane/ethyl acetate 3/2. 
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Spectrum 47. 1H NMR of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine 
(27a). 
 
Spectrum 48. 13C NMR of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine 
(27a). 
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Synthesis of 4-chloro-8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-
c]isoquinoline (28a) 
 
N
N
NH
Cl
O
  
      28a 
 
Triethylamine (0.03 mL, 0.20 mmol) was added to a stirring suspension of (4-
methoxyphenyl)methanamine (2a) (55 mg, 0.40 mmol) in n-butanol (10 mL). After 
stirring for ten minutes N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a) (50 mg, 
0.20 mmol) was added. The reaction mixture was stirred for 19 hours at 100 ºC then 
cooled to r.t., evaporated in vacou and the product purified by flash chromatography on 
silica gel using hexane/ethyl acetate 3/2. This gave 20 mg (40 %) of 4-chloro-8,10a-
epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline (28a) as a colourless 
powder. 
 
1H NMR (CD2Cl2, 600 MHz): δ 8.36 (s, 1H, H-2), 6.55 (dd, J = 5.7, 1.7 Hz, 1H, H-9), 
6.31 (d, J = 5.7 Hz, 1H, H-10), 5.01 (dd, J = 4.5, 1.7 Hz, 1H, H-8), 4.80 (s, 1H, NH), 3.64 
(ddd, J = 11.8, 5.3, 4.1 Hz, 1H, H-6), 2.94 (t, J = 11.8 Hz, 1H, H-6), 1.95 – 1.89 (m, 1H, 
C-6a), 1.71 (dd, J = 11.5, 7.6 Hz, 1H, H-7), 1.53 (ddd, J = 11.5, 4.5, 3.1 Hz, 1H, H-7). 
 
13C NMR (CD2Cl2, 150 MHz): δ 146.3 (C-2), 145.2 (C-4), 144.9 (C-10b), 138.4 (C-9), 
137.9 (CH, C-4a), 135.4 (CH, C-10), 84.2 (C-10a), 78.4 (CH, C-8), 45.4 (C-6), 33.7 (C-
6a), 32 (C-7). 
 
MS EI m/z (rel. %): 235 (100, M+), 218 (25), 206 (47), 192 (60), 166 (20). 
 
HR-MS found, 235.0512 calcd. for C11H10Cl2N3O 235.0518. 
 
M.p. 117 – 119 ºC from dichloromethane. 
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Spectrum 49. 1H NMR of 4-chloro-8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline 
(28a). 
 
 
Spectrum 50. 13C NMR of 4-chloro-8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline 
(28a). 
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Synthesis of N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(34a) and N4,N5-diallyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(34b) 
 
N
N
NH2
N
O
O
N
N
NH
N
O
O
 
      34a                               34b 
 
A solution of 6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine (33a) (60 mg, 0.20 mmol) 
in THF (5 mL) was treated with 65 % NaH (10 mg, ca. 0.20 mmol) in THF (5 mL) at 0oC 
then the mixture was warmed to r.t. and stirred for 20 minutes under N2. Allyl bromide 
(25 mg, 0.20 mmol) and TBAB (70 mg, 0.20 mmol) where added. The mixture was 
stirred for 24 hours at r.t., concentrated in vacou. The products were purified by flash 
chromatography on silica gel using hexane/ethyl acetate 8/1. This gave 11 mg (16 %) of 
N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a) as a 
colourless oil and 26 mg (35 %) of N4,N5-diallyl-6-(furan-2-yl)-N4-(4-
methoxybenzyl)pyrimidine-4,5-diamine (34b) as a colourless oil. 
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N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a) 
 
1H NMR (CD2Cl2, 500 MHz): δ 8.23 (s, 1H, H-2), 7.62 (dd, J = 1.7, 0.7 Hz, 1H, H-5 
furyl), 7.21 (d, J = 8.7 Hz, 2H, H-2 Ar), 7.15 (dd, J = 3.5, 0.7 Hz, 1H, H-3 furyl), 6.83 (d, 
J = 8.7 Hz, 2H, H-3 Ar), 6.60 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 5.92 (ddd, J = 22.9, 
10.4, 5.7 Hz, 1H, CH vinylic), 5.29 – 5.18 (m, 2H, CH2 vinylic terminal), 4.66 (s, 2H, 
NH2), 4.47 (s, 2H, CH2), 3.87 (d, J = 5.7 Hz, 2H, CH2 vinylic), 3.76 (s, 3H, CH3). 
 
13C NMR (CDCl3, 125 MHz): δ 159.3 (C-4, Ar), 157.8 (C-4), 154.4 (C-2, furyl), 147.8 
(C-2), 143.7 (C-5, furyl), 137.5 (C-5), 135.3 (C-H, vinylic), 130.8 (C-1), 129.9 (C-2, Ar), 
128.4 (C-6), 117.9 (CH2, vinylic terminal), 114.2 (C-3, Ar), 112.4 (C-4, furyl), 111.4 (C-
3, furyl), 55.7 (CH3), 52.1 (CH2 or CH2 vinylic), 52 (CH2 or CH2 vinylic). 
 
MS EI m/z (rel. %): 336 (21, M+), 295 (75), 215 (27), 187 (7), 121 (100), 78 (6). 
 
HR-MS found 3361582, calcd. for C19H20N4O2 336.1586. 
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Spectrum 51. 1H NMR of N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a). 
 
Spectrum 52. 13C NMR of N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a). 
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N4,N5-diallyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34b) 
 
1H NMR (CD2Cl2, 600 MHz): δ 8.37 (s, 1H, H-2), 7.66 (dd, J = 1.8, 0.8 Hz, 1H, H-5 
furyl), 7.27 (d, J = 3.5 Hz, 1H, H-3 furyl), 7.19 (d, J = 8.7 Hz, 2H, H-2 Ar), 6.87 (d, J = 
8.7 Hz, 2H, H-3 Ar), 6.65 (dd, J = 3.5, 1.8 Hz, 1H, H-4 furyl), 5.94 – 5.75 (m, 2H, CH N4 
and CH N5), 5.27 – 5.04 (m, 5H, CH2 N4, CH2 N5 and NH ), 4.84 (s, 2H, CH2), 4.25 (d, J 
= 6.1 Hz, 2H, CH2 N4), 3.82 (s, 3H, CH3), 3.68 (d, J = 4.9 Hz, 2H, CH2 N5). 
 
13C NMR (CD2Cl2, 150 MHz): δ 159.4 (C-4 or C-4, Ar), 159.4 (C-4 or C-4, Ar), 153.9 
(C-2, furyl), 150.7 (C-2), 144.1 (C-6), 144.1 (C-5, furyl), 136.4 (CH N5), 135.1 (CH N4), 
131 (C-1), 130.3 (C-2, Ar), 127.4 (C-5), 118.3 (CH2 N5 terminal), 116.8 (CH2 N4 
terminal), 114.4 (C-3, Ar), 113.2 (C-3, furyl), 112.7 (C-4, furyl), 55.9 (CH3), 50.7 (CH2), 
50.2 (CH2 N4), 48.2 (CH2 N5). 
 
MS EI m/z (rel. %): 376 (14, M+), 335 (19), 293 (10), 255 (97), 187 (22), 121 (100), 78 
(5). 
 
HR-MS found 376.1913, calcd. for C22H24N4O2 376.1899. 
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Spectrum 53. 1H NMR of N4,N5-diallyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(34b). 
 
Spectrum 54. 13C NMR of N4,N5-dially-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine 
(34b). 
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Synthesis of 2,6-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) and 4,6-
dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b) 
N
N ClHN
Cl
O
N
N
Cl
NHCl
O
 
               36a                                         36b 
 
A mixture of 2,4,6-trichloropyrimidine (35a) (346 mg, 2.00 mmol), (4-
methoxyphenyl)methanamine (8a) (251 mg, 2.00 mmol), and sodium carbonate (320 mg, 
3.00 mmol) in absolute ethanol (10 mL) was mixed at r.t. for three hours, then evaporated 
in vacou. The residue was dissolved in dichloromethane (3 x 50 mL) and the solution was 
washed with water (2 x 50 mL), dried (MgSO4) and evaporated in vacou. The product 
was purified by flash chromatography on silica gel using 
dichloromethane/ethylacetate/hexane 9/1/20. This gave 253 mg (45 %) of 2,6-dichloro-N-
(4-methoxybenzyl)pyrimidin-4-amine (36a) as a colourless powder and 161 mg (28 %) 
of 4, 6-dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b) as a colourless powder. 
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2,6-Dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) 
 
NMR data collected at 70 ºC 
1H NMR (DMSO-d6, 200 MHz) δ 8.41 (s, 1H, NH), 7.24 (d, J = 8.7, 2H, H-2 Ar), 6.89 
(d, J = 8.7, 2H, H-3 Ar), 6.55 (s, 1H, H-5), 4.43 (d, J = 5.6, 2H, CH2), 3.74 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 50 MHz) δ 163.9 (C-4), 158.6 (C-2 or C-6), 158.4 (C-4 Ar), 157.1 
(C-2 or C-6), 129.5 (C-1), 128.45 (C-2 Ar), 113.7 (C-3 Ar), 102 (C-5), 54.8 (CH3), 43.3 
(CH2). 
 
MS EI m/z (rel. %): 287/285/283 (4/22/34, M+), 252 (7), 136 (10), 121, (100), 78 (8). 
 
HR-MS Found 283.0274, calcd. for C12H11Cl2N3O 283.0279. 
 
Anal.: Found C, 50.77; H, 3.91; N, 14.78. C12H10Cl2N2O2 requires C, 50.72; H, 3.90; N, 
14.79. 
 
M.p. 104.6 – 104.9 °C from hexane/dichloromethane/ethyl acetate 20/9/1 
 
Compound known in literature.88 
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Spectrum 55. 1H NMR of 2,6-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) 
 
Spectrum 56. 13C NMR of 2,6-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) 
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4, 6-Dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b) 
 
1H NMR (DMSO-d6, 300 MHz): δ  8.6 (t, J = 6.2 Hz, 1H, NH), 7.22 (d, J = 14 Hz, 2H in 
Ar), 6.86 (d, J = 11.6 Hz, 2H in Ar), 6.83 (s, 1H, H5), 4.38 (d, J = 6.0 Hz, 2H, CH2), 3.70 
(s, 3H, CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 161.4 (C-2), 160.5 (C-4), 158.3 (C-4 in Ar), 130.7 (C-
1 in Ar), 128.5 (C-2 in Ar), 113.7 (C-3 in Ar), 107.6 (C-5), 55 (CH3), 43.6 (CH2). 
 
MS EI m/z (rel. %): 287/285/283 (4/22/34, M+), 252 (7), 136 (7), 121 (100). 
 
HR-MS Found 283.0277, calcd. for C12H11Cl2N3O 283.0279. 
 
M.p. 146.4 – 146.7 °C from dichloromethane/ethyl acetate/hexane 9/1/20. 
 
Compound known in literature.88 
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Spectrum 57. 1H NMR of 4, 6-dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b). 
 
Spectrum 58. 13C NMR of 4, 6-dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b). 
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Synthesis of 4,6-dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b) 
and 2,6-dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
 
                37a                                     37b 
 
A mixture of 2,4,6-trichloropyrimidine (35a) (290 mg, 1.50 mmol), 4-methoxy1-(4-
methoxyphenyl)-N-methylmethanamine (3a) (151 mg, 1.00 mmol), and triethylamine 
(0.148 mL, 1.55 mmol) in dichloromethane (5 mL) was stirred at -78 °C for four hours, 
then warmed to r.t. over 36 hours and evaporated in vacou. The residue was dissolved in 
dichloromethane (3 x 20 mL) and the solution was washed with water (2 x 50 mL), dried 
(MgSO4) and evaporated in vacou. The products were purified by flash chromatography 
on silica gel using hexane/dichloromethane/ethyl acetate 20/9/1. This gave 150 mg (50 
%)  of 2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) as a 
colourless powder and 55 mg (19 %) of 4,6-Dichloro-N-(4-methoxybenzyl)-N-
methylpyrimidine-2-amine (37b) as a colourless powder.  
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2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
 
NMR data collected at 70 ºC 
1H NMR (DMSO-d6, 500 MHz): δ 7.17 (d, J = 8.7, 2H, H-2 Ar), 6.89 (d, J = 8.7, 2H, H-
3 Ar), 6.78 (s, 1H, H-5), 4.70 (s, 2H, CH2), 3.73 (s, 3H, NCH3), 3.03 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 125 MHz): δ 163.2 (C-4), 158.6 (C-2 or C-6), 158.5(C-2 or C-6), 
158.1 (C-4 Ar), 128.3 (C-2 Ar), 127.8 (C-1 Ar), 113.9 (C-3 Ar), 100.0 (C-5), 54.8 
(OCH3), 51.4 (CH2), 35.2 (CH3). 
 
MS EI m/z (rel. %): 301/299/297 (4/21/25, M+), 282 (6), 176 (3), 121, (100). 
 
HR-MS Found 297.0434, calcd. for C13H13Cl2N3O 297.0436. 
 
Anal.: Found C, 52.27; H, 4.40; N, 13.97. C13H13Cl2N3O requires C, 52.37; H, 4.39; N, 
14.09. 
 
M.p. 90-91 °C from hexane/dichloromethane/ethyl acetate 20/9/1. 
 
 
 
 
 
 136
 
Spectrum 59. 1H NMR of 2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
 
 
Spectrum 60. 1H NMR of 2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
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4,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b) 
 
1H NMR (CDCl3, 300 MHz): δ 7.17 (d, J = 8.4 Hz, 2H Ar), 6.84 (d, J = 8.7 Hz, 2H  Ar), 
6.53 (s, 1H, H5), 4.77 (s, 2H, CH2), 3.78 (s, 3H, OCH3), 3.07 (s, 3H, NCH3).   
 
13C NMR (CDCl3, 75 MHz): δ 161.5 (C-4), 161.2 (C-2), 159 (C-4, Ar), 129 (C-2, Ar), 
129 (C-1, Ar), 114 (C-3 in Ar), 107 (C-5), 55 (OCH3), 52 (CH2), 34.8 (CH3).  
 
MS EI m/z (rel. %): 301/299/297 (3/19/29, M+), 282 (5), 176 (3), 121 (100). 
 
HR-MS Found 297.0436, calcd. for C13H13Cl2N3O 297.0436. 
 
Anal.: Found C, 52.37; H, 4.47; N, 14.01. C13H13Cl2N3O requires C, 52.37; H, 4.39; N, 
14.09. 
 
M.p. 72-74 °C from hexane/dichloromethane/ethyl acetate 20/9/1. 
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Spectrum 61. 1H NMR of 4,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b). 
 
 
Spectrum 62. 13C NMR of 4,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b). 
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Synthesis of 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a), 4,6-dichloro-2-
(4-methoxybenzyloxy)pyrimidine (38b) and  4-chloro-2,6-bis(4-
methoxybenzyloxy)pyrimidine (38c) 
 
                  38a                                   38b                             38c 
 
A solution of p-methoxybenzyl alcohol (4a) (288 mg, 2.00 mmol) in dry THF (5 mL) 
was added over 5 min to a stirring suspension of sodium hydride (88 mg, ca. 65% in oil, 
ca 3.00 mmol) in dry THF (5 mL) under N2. The resulting mixture was stirred at ambient 
temperature under N2 for 1 hour and cooled to 0 oC before the 2,4,6-trichloropyrimidine  
(35a) (2.00 mmol) in THF (5 mL) was added over 15 min. The resulting mixture was 
stirred at r.t. for 12 hours followed by 12 hours at 60 oC. NH4Cl (sat aq., 10 mL) was 
added and the mixture was extracted with dichloromethane (3 × 40 mL), the combined 
organic extracts were washed with NaCl (sat. aq., 10 mL), dried (MgSO4) and evaporated 
in vacou. The products were purified by flash chromatography on silica gel using 
hexane/ethyl acetate 99/1. This gave 197 mg (35%) of 2,4-dichloro-6-(4-
methoxybenzyloxy)pyrimidine (38a) as colourless powder, 118 mg (21%) of 4,4-
dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b) as colourless powder and  22 mg 
(3%) of 4-chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c) as colourless powder. 
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2,4-Dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a) 
 
1H  NMR (DMSO-d6, 300 MHz):δ  7.39 (d, J = 11.6 Hz, 2H in Ar), 7.27 (s, 1H, H5), 
6.94 (d, J = 14Hz, 2H in Ar),  5.34 (2H, CH2), 3.75 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 170.9 (C-4), 160.6 (C-6), 159.5 (C-4, Ar), 158.1 (C-
2), 130.6 (C-2, Ar), 126.8 (C-1, Ar), 113.9 (C-3, Ar), 106.8 (C-5), 69.7 (CH2), 55.1 
(CH3). 
 
MS EI m/z (rel. %): 288/286/284 (2/11/16, M+), 137 (21), 121 (100). 
 
HR-MS Found 284.0113 calcd. for C12H10Cl2N2O2 284.0119. 
 
Anal.: Found C, 50.60; H, 3.59; N, 9.89. C12H10Cl2N2O2 requires C, 50.55; H, 3.54; N, 
9.82. 
 
M.p.73.5 - 73.6 °C from hexane/ethyl acetate 99/1. 
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Spectrum 63. 1H  NMR of 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a). 
 
Spectrum 64. 13C NMR of 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a). 
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4,6-Dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b) 
 
1H  NMR (DMSO-d6, 300 MHz): δ  7.61 (s, 1H, H5), 7.39 (d, J = 8.7 Hz, 2H Ar) 6.94 
(d, J = 8.7 Hz, 2H Ar), 5.31 (2H, CH2), 3.75 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 163.5 (C-2), 162.2 (C-6), 159.4 (C-4, Ar), 130.3 (C-2, 
Ar), 127.1 (C-1, Ar), 114.6 (C-5), 113.8 (C-3, Ar), 69.9 (CH2), 55.1 (CH3). 
 
MS EI m/z (rel. %): 288/286/284 (2 /9/13, M+), 137 (14), 121 (100). 
 
HR-MS Found 284.0120, calcd. for C12H10Cl2N2O2 284.0119. 
 
Anal.: Found C, 49.02; H, 3.47; N, 9.87. C12H10Cl2N2O2 requires C, 50.55; H, 3.54; N, 
9.82. 
 
M.p. 59.6 – 60.5 °C from hexane/ethyl acetate 99/1. 
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Spectrum 65. 1H NMR of 4,6-dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b). 
 
Spectrum 66. 13C NMR of 4,6-dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b). 
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4-Chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c) 
 
1H NMR (DMSO-d6, 300 MHz): δ 7.37 (app. t, J = 8.6 Hz, 2H Ar), 6.93 (app. dd, J = 
3.5 Hz, 4H Ar), 6.76 (s, 1H, H5), 5.31 (app. d, J = 7.7, 4H, CH2), 3.74 (app. d, J = 2.4, 
6H, CH3). 
 
 13C NMR (DMSO-d6, 75 MHz): δ  171.4 (C-2), 163.7 (C-4), 160.5 (C-6), 159.3 (C-4, 
Ar), 159.2 (C-4, Ar), 130.2 (C-2, Ar), 130.1 (C-2, Ar), 127.8 (C-1, Ar), 127.5 (C-1, Ar), 
113.85 (C-3, Ar), 113.8 (C-3, Ar), 100.7 (C-5), 69.0 (CH2), 68.5 (CH2), 55.1 (CH3). 
 
MS EI m/z (rel. %): 388/386 (2,6), 267/265 (2, 6), 137 (3), 121 (100). 
 
HR-MS Found 386.1035, calcd. for C20H19ClN2O4 386.1033. 
 
Anal.: Found C, 61.24; H, 4.70; N, 7.45. C20H19ClN2O4 requires C, 61.22; H, 4.60; N, 
7.51. 
 
M.p. 90.4 – 90.6 °C from hexane/ethyl acetate 99/1. 
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Spectrum 67. 1H NMR of 4-chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c). 
 
 
Spectrum 68. 13C NMR of 4-chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c). 
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Synthesis of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a) 
and 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b) 
N
N ClHN
O
O
N
N NHCl
O
O
 
                  39a                                    39b 
 
A mixture of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a) (320 mg, 1.50 mmol), (4-
methoxyphenyl)methanamine (2a) (200 mg, 1.5 mmol) and triethylamine (0.28 mL, 2.00 
mmol) in absolute ethanol (15 mL) was stirred at r.t. for 24 hours, then evaporated in 
vacuo. The residue was dissolved in dichloromethane (3 x 30 mL) and the solution 
washed with water (2 x 50 mL), dried (MgSO4) and evaporated in vacou. The product 
was purified by flash chromatography on silica gel using dichloromethane/hexane 3/7. 
This gave 234 mg (50 %) of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-
amine (39a) as a yellow oil and 67 mg (14 %) of 4-chloro-6-(furan-2-yl)-N-(4-
methoxybenzyl)pyrimidin-2-amine (39b) as a colourless powder. 
 
Data for 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b) is 
reported on pages 152 - 153.  
 
 
 
 
 
 
 
 
 
 147
2-Chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a) 
 
1H NMR (CDCl3,300 MHz): δ 7.45 (d, J = 0.9 Hz, 1H, H-5 furyl), 7.17 (d, J = 8.6 Hz, 
2H, H-2 Ar), 7.06 (s, 1H, H-3 furyl), 6.83 (s, 1H, H-5), 6.75 (d, J = 8.6 Hz, 2H, H-3 Ar), 
6.43 (dd, J = 3.4, 1.7 Hz, 1H, H-4 furyl), 5.75 (s, 1H, NH), 4.49 (d, J = 5.8 Hz, 2H, CH2), 
3.68 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 161.9 (C-4), 161.6 (C-2), 158.8 (C-4, Ar), 157.3 (C-6), 
151.4 (C-2, furyl), 144.9 (C-5, furyl), 130.7 (C-1), 128.9 (C-2, Ar), 113.9 (C-3, Ar), 
112.5 (C-3, furyl), 112.3 (C-4, furyl), 104 (C-5), 55.2 (CH3), 45 (CH2). 
 
MS EI m/z (rel. %): 317/315 (35/100, M+), 300 (13), 179 (6), 136 (48), 121 (91), 78 (9). 
 
HR-MS Found 315.0779 calcd. for C16H14ClN3O2 315.0775.  
 
Anal.: Found C, 60.91; H, 4.45; N, 13.69. C16H14ClN3O2 requires C, 60.86; H, 4.47; N, 
13.31. 
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Spectrum 69. 1H NMR of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a). 
 
 
Spectrum 70. 13C NMR of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a). 
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Synthesis of 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b) 
and 4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrinidin-2-amine (39c) 
N
NHN
O
O
O
N
N ClHN
O
O
 
                  39b                                     39c 
 
A mixture of tris(diphenylmethyllideacetone)dipalladium (27 mg, 0.030 mmol) and tri(2-
furyl)phosphine (51 mg, 0.22 mmol) was weighed out into a flask. DMF (5 mL) was 
added and the flask flushed with N2. The mixture was stirred for 30 min at r.t., 2,6-
dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36b) (283 mg, 1.00 mmol)  was then 
added to DMF (5 mL) under N2,  and the resulting mixture added to the first mixture. 
Followed by the addition of 2-furyl(tributyl)tin (8a) (380 µL, 1.20 mmol). The mixture 
was then stirred over night at 60 °C (16 hours), and evaporated in vacou. KF (sat. sol. 30 
mL in MeOH) was added and the reaction mixture stirred for a further 16 hours, then 
evaporated in vacou. The product was purified by flash chromatography on silica gel 
using hexane/ethyl acetate 9/1.  This gave 142 mg (45 %) of 4-chloro-6-(furan-2-yl)-N-
(4-methoxybenzyl)pyrimidin-2-amine (39b) as a colourless fluffy powder and 103 mg 
(30 %) of  4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c) as a brown 
oil. 
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 4-Chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b) 
 
1H NMR (CD2Cl2, 300 MHz): δ 7.59 (dd, J = 0.7, 1.7 Hz, 1H, H-5 furyl), 7.29 (d, J = 8.7 
Hz, 2H, H-2 Ar), 7.17 (s, 1H, H-3 furyl), 6.94 (s, 1H, H-5), 6.91 (d, J = 8.7 Hz, 2H, H-3 
Ar), 6.56 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 5.73 (s, 1H, NH), 4.58 (d, J = 5.9 Hz, 2H, 
CH2), 3.78 (s, 3H, CH3). 
 
13C NMR (CD2Cl2,75 MHz): δ 162.6 (C-2), 162 (C-4 or C-6), 159.4 (C-4, Ar), 157.8 (C-
4 or C-6), 152 (C-2, furyl), 145.5 (C-5, furyl), 131.4 (C-1, Ar), 129.2 (C-2, Ar), 114.2 (C-
3, Ar), 112.8 (C-3 or C-4, furyl), 112.7 (C-3 or C-4, furyl), 104.3 (C-5), 55.6 (CH3), 45.3 
(CH2). 
 
MS EI m/z (rel %): 317/315 (36/100, M+), 300 (12), 136 (28), 121, (79). 
 
HR-MS Found 315.0769, calcd. for C16H14ClN3O2 315.0775. 
 
Anal.: Found C, 60.90; H, 4.46; N, 13.26. C16H14ClN3O2 requires C, 60.86; H, 4.47; N, 
13.31. 
 
M.p. 119.5 – 119.5 °C from hexane/ethyl acetate 9/1. 
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 Spectrum 71. 1H NMR of 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b). 
 
Spectrum 72. 13C NMR of 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b). 
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4,6-Di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c) 
 
1H NMR (DMSO-d6, 300 MHz,): δ 7.90 (dd, J = 1.7, 0.7 Hz, 2H, H-5 furyl), 7.78 (t, J = 
6.3 Hz, 1H, NH), 7.32 (d, J = 8.7 Hz, 2H, H-2 Ar), 7.24 (d, J = 3.3 Hz, 2H, H-3 furyl), 
7.19 (s, 1H, H-5), 6.84 (d, J = 8.7 Hz, 2H, H-3 Ar), 6.69 (dd, J = 3.3, 1.7 Hz, 2H, H-4 
furyl), 4.47 (d, J = 6.2 Hz, 2H, CH2), 3.69 (s, 3H, CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 162.2 (C-2), 158 (C-4, Ar), 156 (C-4/C-6), 151.9 (C-2, 
furyl), 145.4 (C-5, Ar), 132.5 (C-1, Ar), 128.8 (C-2, Ar), 113.5 (C-3, Ar), 112.5 (C-4, 
furyl), 111.6 (C-3, Furyl), 55 (CH3), 43.6 (CH2). 
 
MS EI m/z (rel. %): 348/347 (23/100, M+), 332 (22), 211 (6), 121, (17). 
 
HR-MS Found 347.1275, calcd. for C20H17N3O3 347.1270. 
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Spectrum 73. 1H NMR of 4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c). 
 
Spectrum 74. 13C NMR of 4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c). 
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Synthesis of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a), 4,6-dichloro-2-(furan-2-
yl)pyrimidine (40b) 
 
              40a                                      40b                            
 
A mixture of tris(diphenylmethyllideacetone)dipalladium (55 mg, 0.06 mmol) and tri(2-
furyl)phosphine (100 mg, 0.44 mmol) was weighed out into a flask. DMF (10 mL) was 
added and the flask flushed with N2. The mixture was stirred for 30 min at r.t., 2,4,6-
trichloropyrimidine (35a) (360 mg, 2.00 mmol)  was added to DMF (5 mL) under N2  and 
this mixture added to the first mixture, followed by the addition of 2-furyl(tributyl)tin 
(650 µL,  2.05 mmol). The mixture was then stirred over night at 30°C (16 hours), 
evaporated in vacou. KF (sat. sol. in THF 30 mL) was added and the reaction mixture 
stirred for a further 16 hrs, then evaporated in vacou, and subjected to dry flash 
chromatograohy. KF (sat. sol. in THF 30 mL) added and the reaction mixture stirred for a 
further 16 hrs, then evaporated in vacou. The product was purified by flash 
chromatography on silica gel using toluene/dichloromethane/hexane 3/2/1. This gave 230 
mg (55 %) of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a) as colourless crystals, 23 mg 
(5 %)  of 4,6-dichloro-2-(furan-2-yl)pyrimidine (40b). 
 
 
The presence of 4,6-dichloro-2-(furan-2-yl)pyrimidine (40b) was determined by running 
NMR on crude mixture of the two regio-isomers 2,4-dichloro-6-(furan-2-yl)pyrimidine 
(40a), 4,6-dichloro-2-(furan-2-yl)pyrimidine (40b) (Spectra 77). 
 
 
Compound 40b is known in literature.89 
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2,4-Dichloro-6-(furan-2-yl)pyrimidine (40a) 
 
1H NMR (CDCl3, 300 MHz): δ 7.59 (dd, J = 1.7, 0.7 Hz, 1H, H-5 furyl), 7.46 (s, 1H, H-
5), 7.32 (dd, J = 3.6, 0.7 Hz, 1H, H-3 furyl), 6.56 (dd, J = 3.6, 1.7 Hz, 1H, H-4 furyl).  
 
13C NMR (CDCl3, 75 MHz): δ 162.6 (C-4 or C-6), 160.6 (C-4 or C-6), 158.4 (C-2), 
149.4 (C-2, furyl), 146.6 (C-5, furyl), 115.5 (C-3, furyl), 113.1 (C-4, furyl), 112.7 (C-5). 
 
MS EI m/z (rel. %): 216/214 (64/100, M+), 188 (6), 118 (16), 90 (7). 
 
HR-MS Found 213.9700, calcd. for C8H4Cl2N2O 213.9701. 
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Spectrum 75. 1H NMR of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a). 
 
 
Spectrum 76. 13C NMR of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a). 
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Spectrum 77. 1H NMR of crude sample of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a), 4,6-dichloro-2-
(furan-2-yl)pyrimidine (40b). 
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Synthesis of 2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c)  
 
N
N O
O
Cl
 
           40c 
 
2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c) is a result of treatment of the 
“Synthesis of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a), 4,6-dichloro-2-(furan-2-
yl)pyrimidine (40b)” (Page 156) with KF (sat. sol. in methanol) in place of KF (sat. sol. 
in THF), the yield is determined by the length of time the reaction mixture is stirred with 
KF (sat. sol. in methanol), therefore yields are not reported. 
 
 
1H NMR (CDCl3, 300 MHz): δ 7.54 (dd, J = 1.8, 0.7 Hz, 1H, H-5 furyl), 7.28 – 7.20 (m, 
1H, H-3 furyl), 6.89 (s, 1H, H-5), 6.53 (dd, J = 3.5, 1.8 Hz, 1H, H-4 furyl), 4.00 (s, 3H, 
CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 171.5 (C-4), 160.2 (C-6), 157.7 (C-2), 150.6 (C-2, furyl), 
145.2 (C-5, furyl), 113.2 (C-3, furyl), 112.5 (C-4, furyl), 99.3 (C-5), 54.7 (CH3). 
 
MS EI m/z (rel. %): (32/100, M+), 181 (20), 145 (39), 118 (19), 92 (19). 
 
HR-MS waiting on results. 
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Spectrum 78. 1H NMR of 2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c). 
 
Spectrum 79. 13C NMR of 2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c). 
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Synthesis of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-
amine (41a) 
N
N NCl
O
O
 
                 41a 
 
A mixture of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a) (259 mg, 1.20 mmol), 1-(4-
methoxyphenyl)-N-methylmethanamine (3a) (180 mg, 1.20 mmol) and triethylamine 
(0.18 mL, 1.20 mmol) in absolute ethanol (100 mL) was stirred at r.t. for 24 hours, then 
evaporated in vacou. The residue was dissolved in dichloromethane (3 x 30 mL) and the 
solution washed with water (2 x 50 mL), dried (MgSO4) and evaporated in vacou. The 
product was purified by flash chromatography on silica gel using 
hexane/dichloromethane 7/3. This gave 270 mg (68 %) of 2-chloro-6-(furan-2-yl)-N-(4-
methoxybenzyl)-N-methylpyrimidin-4-amine (41a) as a yellow oil. 
 
1H NMR (CD2Cl2, 300 MHz): δ 7.54 (s, 1H, H-5 furyl), 7.17 (m, 3H, H-2 Ar and H-3 
furyl), 6.87 (d, J = 8.6 Hz, 2H, H-3 Ar), 6.71 (s, 1H, H-5), 6.55 (dd, J = 1.7, 3.4 Hz, 1H, 
H-4 furyl), 4.74 (bs, 2H, CH2), 3.77 (s, 3H, OCH3), 3.07 (bs, 3H, CH3). 
 
13C NMR (CD2Cl2, 75 MHz): δ 164.2 (C-4), 160.8 (C-1, Ar or C-2), 159.5 (C-4, Ar), 
156.2 (C-1 Ar or C-2), 152.1 (C-6), 144.9 (C-5, furyl), 128.9 (C-2, Ar), 114.4 (C-3, Ar), 
112.6 (C-4, furyl), 112.2 (C-3, furyl), 94.4 (C-5), 55.6 (OCH3), 52.3 (CH2), 35.8 (CH3). 
 
MS EI m/z (rel. %): 331/329 (16/46, M+), 314 (41), 208 (18), 150 (17), 121, (100), 91 
(7), 78 (11). 
 
HR-MS Found 329.0934, calcd. for C17H16ClN3O2 329.0931.  
Anal.: Found C, 61.78; H, 4.77; N, 12.63. C17H16ClN3O2 requires C, 61.91; H, 4.89; N, 
12.74. 
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Spectrum 80. 1H NMR of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a). 
 
Spectrum 81. 13C NMR of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a). 
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Synthesis of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a) and 4-
chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b) 
 
 
               42a                                    42b 
 
A solution of p-methoxybenzyl alcohol (4a) (288 mg, 2.00 mmol) in dry THF (5 mL) 
was added over 5 min to a stirring suspension of sodium hydride (95 mg, ca. 65% in oil, 
ca 2.20 mmol) in dry THF (5 mL) under N2 and the resulting mixture was stirred at 
ambient temperature under N2 for 1 hour and cooled to 0 oC before 2,4-dichloro-6-(furan-
2-yl)pyrimidine (40a) (430 mg, 2.00 mmol) in THF (5 mL) was added over 15 min. The 
resulting mixture was stirred at r.t. for 16 hours. NH4Cl (sat aq., 10 mL) was added and 
the mixture was extracted with dichloromethane (3 × 40 mL). The combined organic 
extracts were washed with NaCl (sat. aq., 20 mL), dried (MgSO4) and evaporated in 
vacou. The product was purified by flash chromatography on silica gel using 
dichloromethane/hexane 3/2. This gave 332 mg (50 %) of 2-chloro-4-(furan-2-yl)-6-(4-
methoxybenzyloxy)pyrimidine (42a) as colourless powder and 60 mg (10 %) of 4-chloro-
6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b) as a yellow oil. 
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2-Chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a) 
 
1H NMR (CDCl3, 300 MHz): δ 7.44 (dd, J = 1.7, 0.7 Hz, 1H, H-5 furyl), 7.29 (d, J = 8.7 
Hz, 2H, H-2 Ar), 7.14 (dd, J = 3.5, 0.7 Hz, 1H, H-3 furyl), 6.85 – 6.78 (m, 3H, H-3 Ar 
and H-5), 6.43 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 5.27 (s, 2H, CH2), 3.71 (s, 3H, CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 170.8 (C-4), 160.0 (C-2 or C-6), 159.8 (C-4, Ar), 157.7 
(C-2 or C-6), 150.6 (C-2, furyl), 145.2 (C-5, furyl), 130.3 (C-2, Ar), 127.4 (C-1, Ar), 
113.9 (C-3, Ar), 113.1 (C-3, furyl), 112.4 (C-4, furyl), 99.6 (C-5), 69.0 (CH2), 55.2 
(CH3). 
 
MS EI m/z (rel. %): 318/316 (7/22, M+), 122/121 (9/100), 91 (4), 78 (8). 
 
HR-MS Found (waiting on result), calcd. for C16H13ClN2O3 316.0615. 
 
Anal.: Found C, 59.83; H, 4.14; N, 8.76. C16H13ClN2O3 requires C, 60.67; H, 4.14; N, 
8.84. 
 
M.p. 110 -111 °C from dichloromethane/hexane 3/2.  
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Spectrum 82. 1H NMR of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a). 
 
Spectrum 83. 13C NMR of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a). 
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4-Chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b) 
 
1H NMR (CDCl3, 300 MHz): δ 7.50 (d, J = 1.7 Hz, 1H, H-5 furyl), 7.36 (d, J = 8.7 Hz, 
2H, H-3 Ar), 7.23 (d, J = 3.5 Hz, 1H, H-3 furyl), 7.19 (s, 1H, H-5), 6.81 (d, J = 8.7 Hz, 
2H, H-3 Ar), 6.48 (dd, J = 3.5, 1.7 Hz, 1H, H-4 furyl), 5.32 (s, 2H, CH2), 3.71 (s, 3H, 
CH3). 
 
13C NMR (CDCl3, 75 MHz): δ 164.7 (C-2), 162.7 (C-4 or C-6), 159.6 (C-4, Ar), 158.4 
(C-4 or C-6), 150.8 (C-2, furyl), 145.6 (C-5, furyl), 130.3 (C-2, Ar), 128.0 (C-1, Ar), 
113.8 (C-3, furyl and C-3, Ar), 112.7 (C-4, furyl), 108.3 (C-5), 69.6 (CH2), 55.2 (CH3). 
 
MS EI m/z (rel. %): 318/316 (8/23, M+), 180 (23), 122/121 (9/100), 78 (8). 
 
HR-MS Found (waiting on results), calcd. for C16H13ClN2O3 316.0615.  
 
Anal.: Found C, 60.64; H, 4.07; N, 8.55. C16H13ClN2O3 requires C, 60.67; H, 4.14; N, 
8.84. 
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Spectrum 84. 1H NMR of 4-chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b). 
 
Spectrum 85. 13C NMR of 4-chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b). 
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Synthesis of 5-bromopyrimidine-4,6-diol (47a) 
N
N
OH
Br
OH
 
          47a 
 
Bromine (3.0 mL, 60 mmol) in acetic acid (30 mL) was added drop wise to a stirring 
suspension of 4,6-dihydroxypyrimidine (46a) (6.0 g, 54 mmol) in acetic acid (30 mL) at 
70 oC. The mixture was stirred for 24 hours at 70oC, cooled down to room temperature, 
filtered and washed with cold water (200 mL). The filtrate was dissolved in boiling water 
and crystallise out over night. This gave 5.0 g (49 %) of 5-bromopyrimidine-4,6-diol 
(47a) as yellow crystals. 
 
1H NMR (DMSO- d6,300 MHz): δ 12.59 (s, 2H, OH), 8.17 (s, 1H, H-2). 
 
13C NMR (DMSO-d6, 75 MHz,): δ 161.4 (C-4/C-6), 147.9 (C-2), 86.4 (C-5). 
 
MS EI m/z (rel. %): waiting on results. 
 
HR-MS waiting on results. 
 
M.p. 245 – 247 ºC decomposed, from water. 
 
Compound known in literature M.p. 263 – 264 ºC decomposed, from water.83 
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Spectrum 86. 1H NMR of 5-bromopyrimidine-4,6-diol (47a) 
 
 
Spectrum 87. 1H NMR of 5-bromopyrimidine-4,6-diol (47a) 
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Synthesis of 5-bromo-4,6-dichlorpyrimidine (45a) 
N
N
Cl
Br
Cl
 
         45a 
 
5-Bromopyrimidine-4,6-diol (47a) (2.50 g, 13.0 mmol) was dissolved in POCl3 (25 mL) 
with N,N-dimethylaniline (2 mL). The reaction mixture was stirred for 3 hours at reflux, 
quenched by slowly pouring over ice and extracted with ether (100 mL + 3 x 50 mL). The 
organic phase was then shaken with sodium bicarbonate (sat. sol., 200 mL) dried 
(MgSO4) and the product purified by sublimation. For complete purification the product 
was left under high vacuum for 4 days. This gave 1.6 g (54 %) 5-bromo-4,6-
dichlorpyrimidine (45a) as colourless crystals. 
 
1H NMR (DMSO- d6, 300 MHz): δ 6.67 (s, 1H, H-2). 
 
13C NMR (DMSO-d6, 75 MHz): δ 162.2 (C-4/C-6), 155.4 (C-2), 120.7 (C-5). 
 
MS EI m/z (rel. %): 232/230/228/226 (63/100/46/6, M+), 193/191 (24/31), 147 (5). 
 
HR-MS Found 225.8701, calcd. for C4HBrCl2N2 225.8700.  
 
M.p.  79 – 81 ºC from hexane/dichloromethane 6/4. 
 
Compound known in literature M.p. 75 – 76 ºC from sublimation product.83 
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Spectrum 88. 1H NMR of 5-bromo-4,6-dichlorpyrimidine (45a). 
 
 
Spectrum 89. 13C NMR of 5-bromo-4,6-dichlorpyrimidine (45a). 
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Synthesis of 4,6-dichloro-5-methylpyrimidine (48a) 
N
N
Cl
Cl
 
        48a 
 
5-Bromo-4,6-dichloropyrimidine (45a) (200 mg, 0.90 mmol) was added to a flask 
containing THF (30 mL). The flask was flushed with argon and the mixture cooled to -78 
ºC. n-BuLi (1.6 molar solution, 0.7 mL, 1 mmol) was added drop wise to the reaction 
mixture. The mixture was then stirred for 30 min at -78 ºC under argon. Iodomethane 
(0.17 mL, 2.70 mmol) was added to the reaction mixture. The reaction mixture was then 
warmed to r.t. over three hours, quenched NH4Cl (sat. aq., 10 mL), washed with NaCl 
(sat. aq., 2 x 15 mL) and dried (MgSO4). The reaction mixture was evaporated in vacou 
and the product purified by flash chromatography on silica gel using 
hexane/dichloromethane 3/2. This gave 86 mg (59 %) of 4,6-dichloro-5-
methylpyrimidine (48a) as a yellow oil. 
 
1H NMR (CD2Cl2,300 MHz): δ 8.6 (s, 1H, H-2), 8.17 (s, 3H, CH3). 
 
13C NMR (CD2Cl2, 75 MHz,): δ 155.6 (C-4/C-6), 80.6, 80.5, 16.4 (CH3).  
 
MS EI m/z (rel. %): waiting on results 
 
HR-MS waiting on results 
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Spectrum 90. 1H NMR of 4,6-dichloro-5-methylpyrimidine (48a) 
 
Spectrum 91. 13C NMR of 4,6-dichloro-5-methylpyrimidine (48a) 
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7. APPENDIX  
 
Spectrum 92. HMQC of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a). 
 
Spectrum 93. HMBC of 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidine-4-amine (5a). 
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Spectrum 94. HMQC of N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b). 
 
Spectrum 95. HMBC of N4,N6-bis(4-methoxybenzyl)-5-nitropyrimidine-4,6-diamine (5b). 
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Spectrum 96.  HMQC of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-amine (6a). 
 
Spectrum 97.  HMBC of 6-chloro-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidine-4-amine (6a). 
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Spectrum 98. HMQC of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a). 
 
Spectrum 99. HMBC of 2-(furan-2-yl)-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine (9a). 
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Spectrum 100. HMQC of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-amine (10a). 
 
Spectrum 101. HMBC of 4-(furan-2-yl)-N-(4-methoxybenzyl)-N-methyl-5-nitropyrimidin-6-amine (10a). 
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Spectrum 102. HMQC of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a). 
 
Spectrum 103. HMBC of 4-chloro-6-(furan-2-yl)-5-nitropyrimidine (11a). 
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Spectrum 104. HMQC of 4,5-di(furan-2-yl)-5-nitropyrimidine (11b). 
 
Spectrum 105. HMBC of 4,5-di(furan-2-yl)-5-nitropyrimidine (11b). 
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Spectrum 106. HMQC of 4-(furan-2-yl)-6-methoxy-5-nitropyrimidine (11c) 
 
Spectrum 107. HMBC of 4-(furan-2-yl)-6-methoxy-5-nitropyrimidine (11c) 
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Spectrum 108. HMQC of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a). 
 
Spectrum 109. HMQC of 4-(furan-2-yl)-6-(4-methoxybenzyloxy)-5-nitropyrimidine (12a). 
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Spectrum 110. HMQC of 4,6-dichloro-N-methylpyrimidin-5-amine (14a). 
 
Spectrum 111. HMBC of 4,6-dichloro-N-methylpyrimidin-5-amine (14a). 
 
 
 183
 
Spectrum 112. HMQC of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a). 
 
 
Spectrum 113. HMBC of 4,6-dichloro-N-ethylpyrimidine-5-amine (15a). 
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Spectrum 114. HMQC of N-Allyl-4,6-dichloropyrimidin-5-amine (16a). 
 
Spectrum 115. HMBC of N-Allyl-4,6-dichloropyrimidin-5-amine (16a). 
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Spectrum 116. HMQC of 6-chloro-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (17a). 
 
Spectrum 117. HMBC of 6-chloro-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (17a). 
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Spectrum 118. HMQC of 6-chloro-N5-ethyl-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (18a). 
 
Spectrum 119. HMBC of 6-chloro-N5-ethyl-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (18a). 
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Spectrum 120. HMQC of N5-allyl-6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (19a). 
 
 
Spectrum 121. HMQC of N5-allyl-6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (19a). 
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Spectrum 122. HMQC of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a). 
 
Spectrum 123. HMQC of 4-chloro-6-(furan-2-yl)-N-methylpyrimidin-5-amine (20a). 
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Spectrum 124. HMQC of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a). 
 
 
Spectrum 125. HMBC of 4-chloro-N-ethyl-6-(furan-2-yl)pyrimidin-5-amine (21a). 
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Spectrum 126. HMQC of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a). 
 
Spectrum 127. HMBC of 6-(furan-2-yl)-N4-(4-methoxybenzyl)-N5-methylpyrimidine-4,5-diamine (22a). 
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Spectrum 128. HMQC of N5-ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a). 
 
Spectrum 129. HMBC of N5-ethyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (23a). 
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Spectrum 130. HMQC of 4-chloro-6-(furan-2-yl)pyrimidin-5-amine (24a). 
 
 
Spectrum 131. HMBC of 4-chloro-6-(furan-2-yl)pyrimidin-5-amine (24a). 
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Spectrum 132. HMQC of 4,6-di(furan-2-yl)pyrimidin-5-amine (24b). 
 
Spectrum 133. HMBC of 4,6-di(furan-2-yl)pyrimidin-5-amine (24b). 
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Spectrum 134. HMQC of 4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a). 
 
Spectrum 135. HMBC of 4-cloro-6-(furan-2-yl)-N,N-dimethylpyrimidin-5-amine (25a). 
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Spectrum 136. HMQC of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a). 
 
 
Spectrum 137. HMBC of N-allyl-4-chloro-6-(furan-2-yl)pyrimidin-5-amine (26a). 
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Spectrum 138. HMQC of (furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine 
(27a).  
 
Spectrum 139. HMBC of (furan-2-yl)-N4-(4-methoxybenzyl)-N5,N5-dimethylpyrimidine-4,5-diamine 
(27a). 
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Spectrum 140. HMQC of 4-chloro-8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline 
(28a). 
 
Spectrum 141. HMBC of 4-chloro-8,10a-epoxy-5,6,6a,7,8,10a-hexahydropyrimido[5,4-c]isoquinoline 
(28a). 
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Spectrum 142. HMBC of N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a). 
 
Spectrum 143. HMBC of N4-allyl-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34a). 
 
 199
 
Spectrum 144. HMQC of N4,N5-dially-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34b). 
 
Spectrum 145. HMBC of N4,N5-dially-6-(furan-2-yl)-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine (34b). 
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Spectrum 146. HMQC of 2,6-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) 
 
Spectrum 147. HMBC of 2,6-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine (36a) 
 201
 
Spectrum 148. HMQC of 4, 6-dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b). 
 
Spectrum 149. HMBC of 4, 6-dichloro-N-(4-methoxybenzyl)pyrimidine-2-amine (36b). 
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Spectrum 150. HMQC of 2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
 
Spectrum 151. HMBC of 2,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine (37a) 
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Spectrum 152. HMQC of 4,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b). 
 
Spectrum 153. HMBC of 4,6-Dichloro-N-(4-methoxybenzyl)-N-methylpyrimidine-2-amine (37b). 
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Spectrum 154. HMQC of 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a). 
 
Spectrum 155. HMBC of 2,4-dichloro-6-(4-methoxybenzyloxy)pyrimidine (38a). 
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Spectrum 156. HMQC of 4,6-dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b). 
 
Spectrum 157. HMBC of 4,6-dichloro-2-(4-methoxybenzyloxy)pyrimidine (38b) 
 
 206
 
Spectrum 158. HMQC of 4-chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c) 
 
Spectrum 159.  HMBC of 4-chloro-2,6-bis(4-methoxybenzyloxy)pyrimidine (38c). 
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Spectrum 160. HMQC of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a). 
 
Spectrum 161. HMQC of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a). 
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Spectrum 162. NOESY of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (39a). 
 
Spectrum 163. HMQC of 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b). 
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Spectrum 164. HMBC of 4-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39b). 
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 Spectrum 165. HMQC of 4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c). 
 
Spectrum 166. HMBC of 4,6-di(furan-2-yl)-N-(4-methoxybenzyl)pyrimidin-2-amine (39c). 
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Spectrum 167. HMQC of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a). 
 
Spectrum 168. HMBC of 2,4-dichloro-6-(furan-2-yl)pyrimidine (40a). 
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Spectrum 169. HMQC of 2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c). 
 
Spectrum 170. HMBC of 2-chloro-4-(furan-2-yl)-6-methoxypyrimidine (40c). 
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Spectrum 171. HMQC of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a). 
 
Spectrum 172. HMBC of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a). 
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Spectrum 173. NOESY of 2-chloro-6-(furan-2-yl)-N-(4-methoxybenzyl)-N-methylpyrimidin-4-amine 
(41a). 
 
 
Spectrum 174. HMQC of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a). 
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Spectrum 175. HMBC of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a). 
 
Spectrum 176. NOESY of 2-chloro-4-(furan-2-yl)-6-(4-methoxybenzyloxy)pyrimidine (42a). 
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Spectrum 177. HMQC of 4-chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b). 
 
Spectrum 178. HMBC of 4-chloro-6-(furan-2-yl)-2-(4-methoxybenzyloxy)pyrimidine (42b). 
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Spectrum 179. HMQC of 5-bromopyrimidine-4,6-diol (47a) 
 
 
Spectrum 180. HMBC of 5-bromopyrimidine-4,6-diol (47a) 
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Spectrum 181. HMQC of 5-bromo-4,6-dichloropyrimidine (45a) 
 
Spectrum 182. HMQC of 5-bromo-4,6-dichloropyrimidine (45a) 
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